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3Translational research in gynaecological cancer in general, and endometrial cancer in 
particular, has for several years had a solid foundation in Bergen led by Professor 
Helga Salvesen (principal investigator) at the Department of Clinical Medicine, 
University of Bergen and Department of Obstetrics and Gynaecology, Haukeland 
University Hospital. She initiated a systematic collection for a biobank from 
gynaecologic malignancies, at the Department of Obstetrics and Gynaecology, 
Haukeland University Hospital in 2001. After informed consent, freshly frozen 
tumour- and blood samples from women treated for gynaecological cancers were 
prospectively collected at our institution and in a multicentre setting (MoMaTEC).  
Professor Lars Akslen at The Gade Institute, section for Pathology, University of 
Bergen and Department of Pathology, Haukeland University Hospital with his 
Tumour Biology Research Group has been a fundamental collaborator through these 
years. The Tumor Biology Research Group at The Gade Institute led by Professor 
Lars A. Akslen was established in 1995 and has aimed to perform translational cancer 
research at an international level identifying markers of aggressive cancers that can 
assist in prognostication and prediction of targeted treatment response. The biomarker 
studies have been especially related to angiogenesis and tumour-vascular interactions, 
and importance for the metastatic process, and tumour cell proliferation and cell cycle 
regulation. Studies have been performed across different tumour types (breast-, 
endometrial- and prostate cancer and melanoma) with long-time collaboration with 
clinical investigators, and also including international collaboration networks. 
Professor Karl-Henning Kalland at the Gades Institute, University of Bergen, has 
been a long-term collaborator in microarray studies. 
Several international collaborators are today involved in the Studies of pathogenesis, 
prognostic markers and treatment in gynaecologic cancer, led by professor Salvesen; 
Prof. Matthew Meyerson and Rameen Beroukhim, Harvard Medical School, Dana 
Farber Cancer Institute, Boston, USA, are involved in molecular studies and analyses 
of data. 
4Professor Ronald Simon, Prof. University Medical Center Hamburg-Eppendorf, 
Germany; is involved in FISH analyses of identified candidate genes in validation 
series. 
Professor Roman Thomas, Max-Planck Institute for Neurological Research, Cologne, 
Germany, is involved in oncogen mutation screening (Oncomap). 
Members of Nordic Society of Gynaecologic Oncology (NSGO) and European Society 
for Gynaecologic Oncology (ESGO) are recruiting patients for the prospective 
multicentre study, MoMaTEC. 
This international prospective multicentre trial, MoMaTEC (Molecular Markers in 
Treatment of Endometrial Cancer, http://www.clinicaltrials.gov/ct2/show/NCT00598845),
is an important basis of this present thesis. After a period of single centre prospective 
inclusion (Haukeland University Hospital), a multicentre approach was initiated in 
2007 with 10 recruiting centres; Norwegian: Haukeland University Hospital, Bergen, 
St.Olav’s Hospital, Trondheim (MD, PhD S.Tingulstad), Oslo University Hospital, 
Ullevål, Oslo (MD, PhD, Prof. A.Staff) Helse Førde Hospital, Førde (MD, PhD, 
J.Tjugum), Haugesund Hospital, Haugesund (MD, K.Oddenes)  Hospital of Vestfold, 
Toensberg (MD, PhD, J.Rokne), Ålesund Hospital, Ålesund (MD, M.Lode), 
Akershus University Hospital, Oslo (MD, PhD, Prof. M.Engh). 
Collaborating international centres: Gasthuisberg University Hospital, KULeuven, 
Belgium (MD, PhD, Prof. F.Amant) and Sahlgrenska Academy, University of 
Gothenburg, Sweden (MD, PhD, J.Marcickiewicz). 
In relation to Professor Salvesen’s Endometrial cancer research group, at present, 
four theses have been completed, four post-doc projects and six PhD projects 
(including this thesis) are ongoing.  
The Tumor Biology Research Group at The Gade Institute led by Professor Akslen 
currently has 20 members, at present 12 PhDs completed; current supervision: 8 
PhDs, 5 postdocs. 
Main funding sources are Helse Vest, Norwegian Research Council, Norwegian 
Cancer Society and the University of Bergen. 
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7Introduction 
Endometrial cancer is the most common gynaecological malignancy in the western 
world. Although the majority has a good prognosis, still almost 20% recur and one 
third of those dying from the disease were initially classified as early stage disease. 
Endometrial cancer is clearly under-researched in comparison to other cancer types, 
with several aspects regarding optimisation of risk-stratification and treatment, 
surgical as well as systemic, yet to be defined. Several molecular tumour markers 
have earlier been investigated in retrospective series and found to significantly 
influence prognosis, but this knowledge has not yet been incorporated in the clinic. 
In this thesis we have examined markers in preoperative blood samples and routine 
curettage as well as hysterectomy specimens and relation to clinicopathological 
features and patients’ survival. Also, findings in some of these formalin fixed paraffin 
embedded specimens have been related to comprehensive molecular profiling of 
freshly frozen tumour tissue collected in parallel for alterations in important signalling 
pathways related to carcinogenesis. We have investigated endometrial cancers both in 
a population based cohort setting from Hordaland County, Norway and in a large, 
prospective, international multicentre setting. Also alterations in disease 
characteristics as well as treatment strategies have been related to change in survival 
during a 30-years perspective for the population based cohort.  
Our data validate that preoperative markers are significant related to aggressive, 
advanced disease, such as lymph node metastasis, and of potential value in the 
decision making regarding selecting patients for lymph node sampling and adjuvant 
treatment. Biomarkers correlated to activation of specific targetable tumour signalling 
pathways could be of importance for testing targeted therapies. Thus, relevant 
markers should be incorporated in the selection of patients for further randomized 
trials regarding individualised surgical as well as systemic treatment. Also, 
elucidating changes in survival over time in relation to characteristics for the patient 
population is important in the evaluation of treatment strategies.  
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AKT  v-akt murine thymoma viral oncogene homolog, Protein Kinase B 
BMI   Body mass index 
CA-125 Cancer antigen 125 
CT  Computer tomography 
DFS  Disease-free survival 
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MMR  Mismatch repair 
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OS  Overall survival 
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SNP  Single Nucleotide Polymorphism 
TMA   Tissue MicroArray 
TP53  Tumour protein 53, p53  
VB  Vaginal brachytherapy 
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Abstract 
Background: Although endometrial cancer in general has a good prognosis, 15-20% 
recurs. Surgery is the main treatment with lymph node sampling increasingly 
advocated as compulsory for adequate staging. In metastatic disease, there is limited 
effect from systemic therapies including chemotherapy or antihormonal treatment. No 
other targeted therapies are yet available in a routine clinical setting. To improve and 
individualise therapy for this patient group, improved tools for identification of high-
risk patients, to tailor surgery in particular, and identification of targetable molecular 
alterations for development of more effective systemic therapies, are urgently needed. 
Several biomarkers including hormone receptor status, TP53 and Stathmin expression 
have been found to be of prognostic importance in retrospective studies. The 
PI3Kinase signalling pathway is over-expressed in aggressive endometrial carcinomas 
and PI3kinase inhibitors are entering clinical trials for treatment of metastatic disease. 
Main objectives: The main objective was to evaluate if biomarkers, particularly 
examined in a preoperative setting, could identify aggressive endometrial carcinomas, 
especially those with lymph node metastasis. An additional aim was to evaluate 
immunohistochemical markers potentially applicable as markers for response to 
antihormonal therapy and PI3Kinase-inhibitors. Also, we wanted to study changes in 
treatment strategy in relation to survival for endometrial carcinoma patients during a 
30-year period in a population based setting. 
Materials and methods: To evaluate potential biomarkers related to PI3Kinase 
signalling, a population based cohort was investigated for immunohistochemical 
expression of AKT, Phospho-AKT and Stathmin in hysterectomy specimens. These 
markers were also related to level of PI3Kinase signalling based on mRNA 
expression score in a prospective series of 76 patients (Paper I). 
The prospective international multicenter study MoMaTEC; Molecular Markers in 
Treatment of Endometrial Cancer, recruited clinical data, tissue and blood samples 
from 1192 endometrial cancer patients treated at 10 different centres during 2001-
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2010. Preoperative curettage specimens and blood samples have been investigated for 
expression of a panel of potential biomarkers; Stathmin, Estrogen Receptor (ER), 
Progesterone Receptor (PR), TP53 and GDF-15 (Paper II, III and IV). 
Changes in clinicopathological features and treatment were related to survival in a 
population based cohort of endometrial cancer patients from Hordaland County, 
Norway over the last 30 years (Paper V). 
Results: Stathmin overexpression in hysterectomy specimens was strongly correlated 
with characteristics for aggressive disease and poor survival. PI3Kinase signalling 
activation was significantly associated with overexpression of Stathmin. Neither AKT 
nor phospho-AKT expression showed any significant correlations with 
clinicopathological factors nor PI3Kinase signalling levels (Paper I).
Overexpression of Stathmin validated to be correlated with aggressive disease in the 
large prospective multicentre setting (Paper II). Stathmin staining in curettage 
specimens was an independent predictor of lymph node metastases and 
overexpression of Stathmin estimated in curettage and hysterectomy specimens were 
both independent predictors of poor survival.
High preoperative plasma GDF-15 level was significantly associated with aggressive 
disease. Adjusting for age and histological risk factors detected in preoperative 
biopsies, plasma GDF-15 independently predicted risk of lymph node metastasis. 
GDF-15 level also independently predicted poor prognosis (Paper III). 
Pathologic expression of ER, PR and TP53 in preoperative curettage specimen 
correlated significantly with high age at diagnosis, high FIGO stage, non-
endometrioid histology, high grade, metastatic nodes and poor prognosis in a large 
prospective multicenter setting. Double negative ER-PR independently predicted 
lymph node metastasis and poor survival. Even for the most favourable group of 
lymph node negative endometrioid tumours, ER-PR negative status influenced 
survival independent of tumour grade (Paper IV). 
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The number of endometrial cancer patients from Hordaland County increased 
significantly from 1981 through 2010 (Paper V), with a simultaneous increase in 
body mass index and decrease in disease stage at diagnosis. Routinely performed 
pelvic lymph node sampling increased, adjuvant radiotherapy was reduced and 
survival increased significantly during the same period.  
Conclusions: Stathmin immunohistochemical staining is superior to AKT and 
phospho-AKT staining in detecting PI3Kinase signalling activation and endometrial 
carcinomas with poor outcome (Paper I). 
Stathmin staining has been validated to identify endometrial carcinomas with 
aggressive clinic-pathological features in a large multicenter setting. 
Immunohistochemical staining for Stathmin in preoperative biopsies (curettage) 
independently predicts lymph node metastasis and poor survival (Paper II). 
Plasma GDF-15 has been documented as elevated in two independent patient cohorts 
of endometrial cancer patients compared to controls. High preoperative GDF-15 
plasma level was significantly correlated with aggressive subtypes and a significant 
and independent predictor for lymph node metastasis and poor survival (Paper III). 
Double negative hormone receptor status (ER and PR negative) in preoperative 
endometrial cancer curettage has been validated to identify patients with poor 
prognosis in a prospective multicenter setting.  ER-PR status independently predicts 
lymph node metastasis (Paper IV). 
During the 30-year period 1981 through 2010, a reduction in adjuvant radiotherapy 
and increase in routine pelvic lymphadenectomy and curative surgery with advanced 
disease, are associated with improved disease-specific- and overall survival in a 
population-based study of endometrial carcinoma patients with steadily increasing 
body mass index (Paper V).  
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1. Introduction 
1.1 Epidemiology 
Endometrial cancer is a tumour originating from the endometrial lining of the uterus. 
It is the seventh most common malignancy amongst women worldwide, with nearly 
200.000 new cases each year, comprising 4% of all cancers in females. The incidence 
is varying throughout the world being the forth most common cancer in industrialised 
regions after breast, colorectal and lung cancers. Still it is more rare in developing 
countries, supporting that environmental factors contribute to development of the 
disease.1 In developing countries cervical cancer is by far the dominant 
gynaecological malignancy with 453 300 new cases pr year, followed by endometrial 
cancer with 144 900 cases. 1 In western societies endometrial cancer is the most 
common gynaecological cancer, with 142 200 new cases estimated each year and with 
a life-time risk of  approximately 1,6 %1, with comparable figures for Norway 2, as 
illustrated in figure 1. The highest incidence worldwide is seen in USA with more 
than 20/100 000 women each year followed by Europe with 11-14/100 000.3
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Figure 1 Age-adjusted incidence rate (world standard) of endometrial cancer in 
Norway per 100 000 per 5-year period of diagnosis. 
Adapted from Cancer Statistics Norway 2009; http://www.kreftregisteret.no
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Endometrial cancer is very rare in young women as more than 90% of cases occur 
after 50 years of age.3 In the Norwegian Cancer Registry median age at primary 
diagnosis is 66 years with no cases reported before the age of 25, peaking at    
110/100 000 in the 70-74 years age group2, as illustrated in figure 2. 
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Figure 2 Age-adjusted incidence rate of endometrial carcinoma per 100 000 person 
years according to patient age in 5-years groups.  
Adapted from Norwegian Cancer Registry 2008. 2
The overall incidence of endometrial cancer is rising4, 5, as shown for Norway in 
figure 1 and for four of the Nordic countries in figure 3. In Norway, the age-adjusted 
incidence per 100 000 person-years was 13.4 in 1999 and has continued to rise to 17.4 
in 2008.2 Based on observed trends, this is predicted to increase even further the next 
decenniums.6 The overall increase can be explained partly by increased life 
expectancy but possibly also as a consequence of the worldwide epidemic of obesity.  
Endometrial cancer generally has a good prognosis with 5 years survival approaching 
80% in developed and 70% in developing countries.3 In Europe, by large, a stable, 
90% 1-year and 76% 5-years survival has been noted for patients treated 1990-99.7, 8
18
But for the period 1990-2004, the increase in survival ranged from 0.8 to 14.2% in 
data from 10 out of 11 European cancer registries.4  In contrast, the American SEER 
database, reported increased mortality in their population from 1988-2001.9
Figure 3 Age standardised incidence rates of endometrial cancer in the Nordic 
countries per 100 000 according to year of diagnosis.  
Adapted from International Agency for Research on Cancer (IARC) http//www.iarc.fr 
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Figure 4 Age-adjusted world standard incidence rate and mortality for uterine cancer 
per 100 000 from different areas of the world.  
Adapted from Globocan, IACR; http//globocan.iarc.fr
1. 2  Etiology and risk factors 
The majority of endometrial carcinomas are sporadic. Unopposed long-lasting 
estrogen stimulation, not counterbalanced by progesterone, is considered to be a 
major contributing factor to disease development.3, 10, 11 This is supposed to account 
for up to 80% of cases and are often classified as Type I cancers. This entity, with a 
correlation between a hyper-estrogen status and endometrial cancer, was first noted by 
Bokhman 1983.12 He described a group of endometrial cancer patients with 
overweight, hyperlipidemia, diabetes mellitus and signs of hyper-estrogenism: 
20
hyperplasia of the background endometrium, low grade tumours and sensitivity to 
progestogens. These patients had an over-all good prognosis. In contrast, the tumours 
classified as Type II cancers, were more often undifferentiated (high grade), deeply 
invading the myometrium, metastatic at time of diagnosis and developing in a 
background of atrophic endometrium. The Type II patients had little response to 
progesterone therapy and poor survival. The distinction between these two types was 
later utterly refined by histopathological subtyping and immunohistochemical 
profiling: high proportion of endometrioid histological subtype, estrogen and 
progesterone receptors positivity in Type I cancers while Type II cancers were 
dominated by non-endometrioid histological subtypes including serous papillary, clear 
cell and undifferentiated subtypes, and loss of hormone receptors.13, 14
Excess estrogen relative to progesterone stimulates endometrial-cell proliferation, 
inhibits apoptosis and promotes angiogenesis5,15, all processes in favour of 
carcinogenesis. Conditions leading to long-term estrogen overexpression relative to 
the expression of progesterone promote increased risk of Type I endometrial cancer: 
obesity, persistent anovulation, nulliparity, tamoxifen use and HRT without 
concomitant progestin substitution. Factors associated with relative less estrogen 
stimulation are associated with decreased risk: multiparity and use of oral 
contraceptives. In addition, smoking, high coffee intake and physical exercise is 
correlated with reduced risk.5, 16-19 It has been estimated that each 5 kg/m2 increase in 
body weight approximately doubles the risk of developing endometrial cancer, RR 
1.95.20 Although overweight is linked with increased incidence of endometrial cancer, 
the link between obesity and survival after endometrial carcinoma treatment is less 
clear. Overweight patients have been reported to be younger, with less advanced 
tumours and lower histological grade at diagnosis, factors all in favour of a better 
prognosis.21, 22
Women with breast cancer, and in particular those treated with Tamoxifen, also have 
increased risk of developing endometrial cancer. Although estrogen may act as a 
common risk factor for both cancer types, subsequent endometrial cancers following 
breast cancer are more often of Type II (OR 2.6).23
21
For the Type II cancers, mainly non-endometrioid subtypes, the tumour arises on basis 
of atrophic endometrium, patients are not prone to over-weight, and a different 
precursor lesion, endometrial glandular dysplasia, has been described.24 For this 
group, the hypothesis of a hyper estrogenic environment leading to cancer 
development is not applicable, and no alternative etiologic hypothesis has been 
established. 
Although having first grade relatives with endometrial cancer approximately doubles 
the cancer risk25, the majority of endometrial carcinomas has no known genetic basis 
and as such occurs sporadic. A minority of endometrial cancers, 2-9%, has been 
linked to the Lynch syndrome; hereditary non-polyposis colorectal cancer (HNPCC) 
with autosomal germline mutations in genes responsible for DNA mismatch repair 
(MMR genes).26, 27 Endometrial cancer is the commonest extra-colonic cancer 
manifestation in these women, with a lifetime risk of 40-70%. For females with germ 
line mutations in MMR genes, yearly screening with endometrial biopsy is 
recommended, although firm survival benefit is not yet documented.28 Prophylactic 
hysterectomy and oophorectomy is recommended by some after completed 
childbearing but before natural menopause, although evidence from randomised trials 
are lacking.5, 29, 30
Screening for endometrial cancer in the general population is not recommended. 
1.3 Clinical aspects and diagnostics 
Abnormal vaginal bleeding is the most common incident symptom in endometrial 
cancer, present in more than 90% of patients. Irregular bleeding is frequent in the pre-
menopausal period, mostly due to transient hormonal disturbances. In contrast, 
postmenopausal bleeding is an alarming symptom urging most women to seek 
medical care. Endometrial carcinoma will be present in nearly 10% of these patients, 
with increasing proportion by age and time from menopause or with recurrent 
bleeding episodes.31-33  
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1.3.1 Biopsy, cytology and curettage
Endometrial cancer is diagnosed by biopsy from the uterine lining; slim plastic 
curettage devices are feasible for out-patient diagnostics with a sensitivity of 81-99% 
and specificity of 98%.5, 34, 35 If the material is sparse or otherwise unfit for 
histopathological diagnosis, a formal curettage procedure with specimens collected 
from the cervix and uterine body separately (fractionated curettage) is performed. By 
bimanual palpation, size of the uterus is estimated and a rough assessment of the 
uterine mobility performed as part of the evaluation of operability. Endometrial 
cytology may accurately discriminate cancer from benign lesions but supplementary 
biopsy is necessary for optimal histologic subtyping and grading. Hysteroscopy may 
also be used to retrieve biopsies and has been described to detect cancer with a 
sensitivity of 86% and a specificity of 99%. There is a theoretical risk of spreading 
cancer intra-abdominally along with flushing of fluid used by hysteroscopy, although 
this has not been linked to reduced prognosis.36 Thus hysteroscopy will often be 
applied for those patients where other methods have been inconclusive. 
The histopathological diagnosis of cancer in the endometrial mucosal biopsy is the 
cornerstone in the diagnostic algorithm; this will initiate the planning of further 
treatment. Proper classification of histological subtype and grade is strongly 
recommended as part of the preoperative work up; non-endometrioid subtypes 
including serous papillary, clear cell and undifferentiated subtypes as well as 
carcinosarcomas are aggressive, with high frequency of extra-uterine spread.37
Likewise high grade endometrioid tumours dominated by nuclear atypia and solid 
growth are correlated with high FIGO stage and poor prognosis.38 Proper identifying 
high-risk subtypes is important to allocate patients for appropriate surgical treatment 
at tertiary centres as indicated.39, 40 The correlation between preoperative assessment 
based on biopsy/curettage and postoperative evaluation of the hysterectomy 
specimens varies. Wang and co-workers41 described accuracy as low as 37% for 
detecting correct grade preoperatively compared to final grade based on hysterectomy 
specimen. Although accuracy increased with higher grade, overall 50% were 
upgraded. Using frozen section increased the concordance to 69%. Corresponding 
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figures from other studies indicate an accuracy of 64-71% for grade and 58-85% for 
frozen section.42-44
1.3.2 Sonography 
Sonography by an experienced gynaecologist is a good diagnostic tool to evaluate the 
possibility of cancer as the cause of a postmenopausal bleeding.  A thin, regular 
endometrial lining <4 mm measuring the double endometrial thickness33, corresponds 
to a probability of 1 % for having cancer, reduced to 0.7% if a cut-of of <3 mm is 
applied.35 The evaluation of premenopausal patients is more challenging due to 
cyclical changes in endometrial thickness.  
Cervical or myometrial tumour infiltration can be assessed preoperatively by 
ultrasound with an accuracy of 92-98% and 77-84% respectively.45-48 If cervical 
infiltration is detected, this opts for extended surgical treatment with radical 
hysterectomy including excision of paracervical and parametrial structures, similar to 
the surgical treatment of primary cervical cancer. Tumour infiltrating deeply in the 
myometrium (>50% of the wall thickness) significantly increases the risk of lymph 
node metastasis.49, 50 This is one key factor evaluated in many algorithms for decision-
making regarding lymphadenectomy in connection with the primary surgical 
treatment.51-53
1.3.3 Radiological diagnostics  
Chest X-ray or CT (computer tomography) is recommended preoperatively to detect 
distant spread including lung metastasis. Pelvic- MRI (Magnetic Resonance Imaging) 
is superior to CT in evaluating extent of pelvic disease.46, 54 At present neither is 
considered a good predictor of lymph node metastasis. 
The accuracy of MRI evaluation of cervical or myometrial tumour infiltration is in 
line with what can be achieved by Sonography. For both modalities the prediction of 
cervical infiltration is better than for myometrial infiltration.46, 48
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1.3.4 Serological analyses 
Serological analyses are not used routinely in the diagnostic work-up of endometrial 
cancer. Still there are some reports supporting CA-125 as a predictor of patients with 
high risk features, including lymph node metastases. In one study of 124 patients, a 
preoperative level of CA-125 >40 U/ml correlated significantly with advanced stage, 
deep myometrial infiltration and lymph node metastasis, predicting metastatic lymph 
nodes with a sensitivity of 71% and specificity of 81%.55 A more recent study found 
that CA-125 with a cut-off >23.3 U/ml similarly predicted lymph node metastasis 
with a sensitivity of 65%, specificity of 64% and accuracy of 65% analysing only 
patients with endometrioid tumours.56
1.4 Treatment 
1.4.1 Surgery, including lymphadenectomy  
Surgery is the main component in primary treatment of endometrial cancer. 
Hysterectomy with bilateral salpingo-oophorectomy is performed if the patients’ 
general co-morbidity does not preclude this. Peritoneal washing for cytological testing 
is recommended. Extended radical hysterectomy including excision of paracervical 
and parametrial structures is performed if tumour tissue invades the cervix, in line 
with the surgical approach to treatment of cervical cancer. With a histologic diagnosis 
of clear cell or serous papillary subtypes, resection of the omentum is also 
recommended due to high frequency of intra-abdominal spread of these subgroups.40, 
57-59  
Traditionally, primary surgery has been performed by laparotomy, but may also be 
performed by laparoscopy, laparoscopic assisted vaginal hysterectomy or robotic 
assisted laparoscopic technique, according to the patient status and surgeons’ skills, 
preferences and availability of equipment (robotics). Laparoscopic procedures 
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generally have longer operation time but less blood loss and shorter hospital stay.60, 61
Long-term outcome comparisons are sparse and awaiting.  
According to the FIGO recommendations62-64, pelvic and para-aortic lymph node 
sampling should be performed as part of complete surgical staging. The proportion of 
patients where this is actually performed varies considerable. Even in centres strongly 
advocating this procedure it is still not performed for 34-49% of patients.65, 66 A 
survey among tertiary cancer centres in USA reported that 45% of centres routinely 
performed lymphadenectomy67, with corresponding numbers reported from European 
centres of 24%.68 One of the latest reports from the large SEER database (USA)9, 
describes an increasing rate of lymphadenectomy performed from 25% in 1988 to 
44% in 2001 with mean number of nodes harvested of 6. In Norway the national 
guidelines from 2002 recommended sampling if suspicious enlarged nodes were 
encountered during surgery.57 In the revised guidelines from 2009 a risk stratification 
based on endometrial subtype and grade and myometrial infiltration recommends 
pelvic lymph node sampling for medium-risk patients, and pelvic and para-aortal 
lymphadenectomy for high-risk patients40, see table 1.  
Table 1 Risk of recurrence, stratification in relation to histological subtype and grade 
and myometrial infiltration. 
Adapted from the Norwegian Gynaecological Society’s Guidelines;
http://www.legeforeningen.no/ngf
 Myometrial infiltration 
<50% 
Myometrial infiltration 
>50% 
Endometrioid Grade 1-2 Low-risk Medium-risk 
Endometrioid Grade 3 Medium-risk High-risk 
Clear cell, serous papillary,  
undifferentiated, carcinosarcoma
High-risk High-risk 
It is well documented that metastatic lymph nodes, corresponding to FIGO stage IIIC 
is a strong predictor of poor prognosis with 57% 5-years survival compared to 91 % 
for FIGO IA/IB, 85% for IC, 83%for IIA and 74% for FIGO stage IIB.49  
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Factors known to correlate with lymph node metastases are high grade endometrioid 
tumours and non-endometrioid histological subtypes.50, 69 Also, cancers infiltrating 
deeply in the myometrium are more prone to lymph node spread.49, 50 The reported rate 
of metastatic lymph nodes is 6% for <50% myometrial infiltration compared to 12 % 
for >50% infiltration and 40% for the subgroup of histological grade 3 tumours with 
deep infiltration. The risk of para-aortic metastasis without concomitant pelvic lymph 
node positivity was generally low: 0.3-2.9%, highest for grade 3 tumours suggesting 
that systematic sampling of para-aortic lymph nodes will improve prognostication for 
this subgroup of patients.49
Although detecting the presence of metastatic lymph nodes identifies patients with 
poor prognosis, it is still a matter of debate whether removing lymph nodes 
(performing lymphadenectomy) improves outcome. There are cohort studies showing 
better survival for patients where lymph nodes have been removed 70, 71 but most 
cohort studies do not find any significant survival differences comparing FIGO stage I 
patients with or without lymph node sampling performed.51, 70, 72-77 For summary see 
table 2. 
Two large randomised trials of lymphadenectomy have been performed, neither 
finding any survival benefit for lymph node sampled patients.78, 79 Also investigation 
of the pooled data showed no significant survival differences with HR = 1.07 (95% 
CI 0.81-1.43) and HR = 1.23 (95% CI 0.96 -1.58) for overall and recurrence-free 
survival respectively.80 Lymphadenectomy has, however, been linked to higher 
complication rates: for the sampled group of patients a significantly higher risk for 
surgically related systemic complications and lymph oedema or lymph cysts formation 
has been reported with RR = 3.72 (95% CI: 1.04-13.27) and RR = 8.39 (95% CI: 
4.06-17.33) respectively. 
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Table 2 Studies comparing outcome of lymph node sampling (LNS+) versus no 
lymph node sampling (LNS-) in treatment of endometrial carcinoma. 
      Survival Impact 
1. Author/ 
Year Inclusion 
Study/ 
Periode 
Outcome 
measure 
LNS-  
n/% 
LNS+ 
n/% 
Log-rank 
p-value 
Multivariate  
analysis 
Cusido  Endometrioid Retrospective   n=85 n=143  
HR 
LNS+  
P-
value 
201174  1990-2008 DSS 93% 93% n.s n.a n.a 
Bassarak  Endometrioid Retrospective  n=63 n=151    
201076  1990-2002 DSS FIGO I 90% 95% 0.032 0.31 0.005 
   DSS all 85% 90% 0.044   
   OS FIGO I 70% 95% 0.001   
   OS all  60% 85% 0.001 0.40 0.001 
   PFS FIGO I 92% 94% 0.69   
   PFS all    0.38 0.022 
Kang  Endometrioid Retrospective  n=58 n=64  n.a  
200977 Grade 1-2 2002-2004 PFS 98% 97% 0.61   
 <50% MI ( MRI)  OS 98% 98% 0.95   
Neubauer  Endometrioid Retrospective  n=313 n=268    
200983 Grade1 1970-2006 PFS 89% 90% ns 0.96 0.82 
   OS 93% 92%  1.00 0.99 
Kitchener  Clinical stage I Prospective  n=704 n=704    
200979  RCT 1998-05 OS 81% 80%  1.04 0.83 
  Multicenter RFS 79% 73%  1.25 0.14 
Panici  Clinical stage I Prospective  n=250 n=264    
200878  RCT 1996-06 DSS 82% 81% 0.68 1.20 0.41 
  Multicenter OS 90% 86% 0.50 1.16 0.59 
Zuzterzeel  FIGO I / II Retrospective  n=123 n=172  
LNS 
n.s.   
200884 Intermedian/ 2 centres PFS 87% 84% 0.46   
 High risk 1983-2004       
Chan  Endometrioid Prospective  n=27 063 n=12 333    
200770  Multicenter DSS FIGO I 97% 96% >0.05 0.75 <0.001 
  1988-2001 DSS FIGO II 82% 90% <0.0001   
   DSS FIGO III 63% 74% <0.0001   
   DSS FIGO IV 27% 53% <0.0001   
Denschlag  FIGO III Retrospective  n=51 n=60    
200771  1989-2003 DSS 59% 73% 0.039 0.33 0.017 
Hidaka  Endometrioid Retrospective  n=60 n=68  n.a  
200772 G1-2,<50%MI 1992-3003 DSS 98% 96% 0.56   
   OS 98% 99% 0.66   
Ceccaroni  Clinical stage I  Retrospective  n=76 n=55  n.a  
200473  1986-1994 OS 88% 93% 0.38   
Mariani  Endometrioid Retrospective OS n=141 n=187    
200051 Grade 1-2  1984-1993 Tumour <2cm 100% 100% 1.00 n.s  
 <50%MI  
OS  
Tumour >2cm 100% 93% 0.10   
   
RFS 
Tumour>2cm 100% 91% 0.05   
Bar-Am  Endometrioid Retrospective  n=62 n=183    
199875 Clinical Stage I  1980-1989 OS 89% 88% 0.88 n.a  
n.a: not accounted for, n.s: not statistical significant, p-value unspecified, HR: Hazard ratio, DSS: Disease-
specific survival, OS: Overall survival, PFS: Progression-free survival, RFS: Recurrence-free survival 
Blue: Randomised controlled trials, Red: p-value <0.05 
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Still, uncertainties related to the standardisation of the procedures applied for lymph 
node sampling and lymphadenectomy, as well as a potential therapeutic effect for 
specific subgroups of patients, and for high risk groups in particular, is still debated.81
Alternative approaches to identify patients of high risk for lymph node metastasis by 
applying intra-operative investigations have been attempted. Unfortunately, the 
detection of deep myometrial infiltration by the surgeon based on visual inspection 
has been described with as low as 30% accuracy for Grade 3 tumours82, while the 
pathologist based on frozen sections had 85% concordance.44
1.4.2  Adjuvant treatment 
Radiation therapy 
Radiation therapy can be delivered vaginally as brachytherapy (VB), externally to the 
pelvis (EBRT), or extended to include the para-aortal area or the whole abdomen. 
Radiation therapy is mostly used as adjuvant treatment aiming to decrease the risk of 
local and regional relapse. Medically inoperable patients may be considered for 
radical radiotherapy.  
A Cochrane review including four randomised controlled trials of patients with FIGO 
stage I disease treated with external pelvic radiation versus no adjuvant treatment 
showed a significant reduction of vaginal relapse for the treatment group (RR=0.28; 
95% CI 0.17-0.44) but no overall improvement of survival. Patients in the treatment 
arm with multiple high risk factors as deep myometrial infiltration and grade 3 
tumour, had a trend towards improved survival compared to the controls.85 Based on 
this, radiation therapy is no longer recommended for low-risk patients with FIGO 
stage I endometrioid grade 1 disease with less than 50% myometrial infiltration. The 
PORTEC-2 trial demonstrated that vaginal brachytherapy was as efficient as external 
radiation in reducing local recurrences but with fewer side effects for high-
intermediate risk patients defined as FIGO stage I grade 1-2 with deep infiltration, 
grade 3 with <50% infiltration or FIGO stage II with superficial infiltration of grade 
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1-2.86 A trend for shift in treatment regimen in favour of vaginal brachytherapy rather 
than external radiation therapy has been documented.87 For the time being only high 
risk groups within FIGO stage I defined as grade 3 endometrioid tumours with deep 
myometrial infiltration or non-endometrioid histological subtypes are considered for 
external radiation therapy88, in line with the revised Norwegian National guidelines40
In line with the international trend, there has clearly been a reduction in the use of 
adjuvant radiotherapy in Norway from routinely applied in the vast majority of 
endometrial carcinoma patients through a period with administration of radiotherapy 
to intermediate- and high risk groups until current practice.89 (Trovik, Paper V) 
Systemic therapy 
Anti-hormonal therapy is no longer advocated as adjuvant treatment for endometrial 
cancer. Two Cochrane reviews have addressed this; Kokka and co-workers reported 6 
randomised controlled trials with different regimens in adjuvant or recurrent setting 
and found insufficient evidence for any survival benefit90, but in five out of these six 
trials hormone receptor status was not incorporated. Martin-Hirch and colleagues 
reported seven randomised trials of gestagen therapy in a pooled meta analysis finding 
no survival benefit from adjuvant treatment with gestagens91. It should be noted, 
however, that none of these randomised trials were based on hormone receptor status 
in the tumours or metastatic lesions, so anti-hormonal treatment might have a yet 
unexplored potential for subgroups of receptor positive endometrial carcinoma 
patients.  
Chemotherapy for high-risk endometrial patients is increasingly recommended. A 
recent Cochrane review of 9 randomised controlled trials of adjuvant chemotherapy, 
mostly platinum based, describes significant survival improvement for patients treated 
with chemotherapy, both alone or in addition to radiation therapy. Overall survival 
HR was 0.74 (95% CI 0.64-0.89) and progression-free survival 0.75 (95% CI 0.64-
0.89) in favour of chemotherapy.92 The risk of recurrence outside the pelvis was 
significantly reduced with chemotherapy while pelvic recurrence tended to be better 
prevented by radiation therapy although not statistical significant (RR=1.28; 95%CI 
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0.97-1.68). The reported proportion of patients receiving adjuvant chemotherapy has 
also increased, from 2 to 13% from 1996 to 2001.49  
Despite the introduction of more extensive primary surgery and adjuvant 
chemotherapy for high risk groups, treatment of patients with advanced or recurrent 
disease generally have an unfavourable outcome; with 5-year survival of 36-57% for 
FIGO stage III and 20-21% for FIGO stage IV.93  
The exception is an isolated vaginal recurrence where radiation therapy in former 
radiation naïve patients has a similar survival as if radiation is administered as a 
primary adjuvant treatment.94
One study (GOG 19) regarding patients with measurable recurrent or advanced 
endometrial cancer tested continuously administered tamoxifen citrate and progestin 
intermittently found a significant longer survival for patients with pre-treatment 
tumour biopsies positive for estrogen receptor with HR 0.47 (95% CI 0.24-0.92), 
median overall survival of 8 months  versus 19 months with negative ER.95
The searching for better treatment regimens has prompted investigation of underlying 
molecular alterations important in endometrial carcinogenesis.96 Exploration of 
tumour biology, uncovering dysregulation in several cellular pathways, is one way of 
identifying novel treatment strategies. Several of such molecular approaches to new 
therapy are now being explored in clinical phase I and II trials. Of studies recently 
completed evaluating therapies in recurrent or metastatic setting, the partial response 
rate range from 5-12.5 % and stable disease from 10-49%.97 Ongoing studies are 
mostly exploring EGFR, VEGF or mTOR/PI3Kinase as shown in table 3. 
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Table 3 Ongoing Phase I/II trials of targeted therapies for endometrial cancer. 
Clinical trial ID Target Biological Agent 
Additional 
treatment n 
Restricted to 
biomarker 
NCT00920257 AKT GSK2141795  70*  
NCT01476137 AKT&MEK GSK1120212, GSK2110183  335*  
NCT01138085 AKT&MEK GSK1120212, GSK2141795  40*  
NCT01273168 ER Endoxifen  72* ER/PRstatus 
NCT00003669 ER Arzoxifene  n.a.  
NC 00006903 ER Fulvestrant  95 ERstatus 
NCT01244438 FGFR FP-1039  10 FGFR2mutation 
NCT01454479 HER2 Lapatinib  Ixabepilone 24 HER2pos 
NCT00650572 HER2/EGFR ARRY-380  50* HER2 pos 
NCT00087685 mTORC1 Everolimus  35  
NCT00703807 mTORC1 Everolimus Topotecan 36  
NCT01068249 mTORC1/ER Everolimus, Letrozole  42  
NCT00770185 mTORC1 Ridaforolimus  30  
NCT00739830 mTORC1/ER-PR Ridaforolimus, MP/M C/P,PLD,D,To 130  
NCT01256268 mTORC1 Ridaforolimus C/P 28*  
NCT00408655 mTORC1 Temsirolimus  39*  
NCT00729586 mTORC1/ER-PR Temsirolimus, M,T  84  
NCT01460979 mTORC1 Temsirolimus  86*  
NCT00703625 mTORC1 Temsirolimus Docetaxel 25*  
NCT00982631 mTORC1 Temsirolimus PLD 30*  
NCT00703170 mTORC1 Temsirolimus PLD 25*  
NCT01155258 mTORC1 Temsirolimus VD 20*  
NCT01198184 mTORC1/ Notch Temsirolimus, RO4929097  30*  
NCT00698243 mTORC1/2 OSI-027  110*  
NCT00687687 PARP BSI-201 C/P 45  
NCT01237067 PARP Olaparp Carboplatin 66*  
NCT01289041 PI3K BKM120  140 PI3K activation 
NCT01068483 PI3K BKM120  86*  
NCT00876109 PI3K GDC-0941  99*  
NCT01458067 PI3K GSK2636771  150* PTEN loss 
NCT01312753 PI3K MK-2206  90 PI3CA mutation 
NCT01307631 PI3K MK-2206  90 PI3CA mutation 
NCT00756847 PI3K XL 147 C/P 74*  
NCT01364844 PI3K/mTOR DS-7423  66*  
NCT01455493 PI3K/mTOR GDC-0980  50  
NCT00940498 PI3K/mTOR PKI-587  85*  
NCT00485719 PI3K/mTOR XL765   75*  
NCT00462826 VEGF Aflibercept  43  
NCT00879359 VEGF Bevacizumab  C/P 31  
NCT00545792 VEGF Bevacizumab Radiation therapy 20*  
NCT00513786 VEGF Bevacizumab C/P 38  
NCT01379534 VEGF Dovitinib  80 FGFR2mutation 
NCT00977574 VEGF/mTOR Bevacizumab, Temsirolimus C/P/Ixabepilone 330  
NCT01010126 VEGF/mTOR Bevacizumab, Temsirolimus  275*  
NCT00723255 VEGF/mTOR Bevacizumab, Temsirolimus  43  
NCT01065662 VEGF/mTOR Temsirolimus, Cediranib  50*  
NCT01225887 VEGFR/FGFR2 Intedanib  55  
NCT00888173 VEGFR2 Brivanib  43  
NCT01132820 VEGFR2 Cediranib  54  
NCT01111461 VEGFR2 E7080  130  
NCT00478426 VEGFR2 Sunitinib  30  
T
ID= ClinicalTrial.gov identifier, n=number of patients to be included, n.a=not accounted for  
AKT=v-akt murine thymoma viral oncogene homolog, FGFR= fibroblast growth factor receptor, ER=estrogen receptor, 
EGFR=epidermal growth factor receptor, HER2=human epidermal growth factor receptor 2, MAP2K1=mitogen-
activated protein kinase kinase 1, mTORC=mamillian target of rapamycin complex, PARP=poly (ADP-ribose) 
polymerase, PI3CA=phosphoinositide-3-kinase catalytic alpha polypeptide, PI3K=phosphoinositide-3-kinase, 
PR=progesterone receptor, PTEN=phosphatase and tensin homolog, VEGF= vascular endothelial growth factor 
C/P=Carboplatin/Paclitaxel, D=Doxorubicin, M=Megestrol, MP=Medroxyprogesteron, PLD= Pegesylated Doxorubicin, 
T=Tamoxifen, To=Topotecan, VD= Vinorelbine ditartrate, *Including other tumour types 
 
1.5 Tumour biology 
Normal cells have a highly controlled behaviour, following strictly regulated steps. 
External signal molecules (ligands) trigger receptors leading to propagation of signals 
through intracellular circuits (pathways) finally resulting in changes in gene 
expression in the cell nucleus followed by altered protein production. These cell-
signalling pathways are tightly controlled via several feedback loops. When cancer 
develops, the cell escapes these strict regulatory mechanisms due to multistep changes 
in the cell’s DNA, as pinpointed in the phrase; “Cancer is a genetic disease at the 
cellular level”.98 Still, tumour cells will be influenced by the local tissue environment, 
micro milieu, favouring different cell clones to thrive in different tissues or remain 
dormant.99 Six specific traits or hallmark characteristics acquired during the multistep 
cancer development have been described: self-sufficiency in growth signals, 
insensitivity to anti-growth signals, evasion of apoptosis, unlimited replicative 
potential, sustained angiogenesis and tissue invasion and metastasis.100 Recently the 
ability to evade immunological destruction and reprogramming of energy metabolism 
to support neoplastic proliferation have been suggested as emerging additional 
hallmarks of cancer. Also, two enabling characteristics, tumour-promoting 
inflammation and genome instability and mutation have been introduced to the model 
of Hanahan and Weinberg.101 Targeted therapies (developed against specific 
molecular targets) can be categorized according to their hallmark capabilities as well 
as the main signalling pathway it attacks.  
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An illustration simplifying the principles of a signalling pathways and effects of 
oncogenes and tumour suppressors is seen in figure 5. 
Carcinogens may result in genetic changes through gene mutations, deletions, 
translocations, amplifications or change of gene transcription through epigenetic 
alterations. Three different categories of genes are typically affected during the 
carcinogenetic process: oncogenes, tumour suppressor genes and care-taker genes.99   
Figure 5 Signalling pathway: Extracellular signal substance (ligand), connecting to 
receptor, activating intracellular effectors (phosphatases, kinases or ubiquilators) and 
nuclear transcription factors linked to protein production. 
1.5.1 Oncogenes
Normal genes (proto-oncogenes) may be changed to oncogenes by mutation, deletion, 
translocation or amplification. Activation of one allele of a gene pair is sufficient to 
alter the affected gene’s transcription, and thus lead to changed protein production 
(oncoproteins); either as uninhibited increased quantity or with increased or 
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unregulated activity due to structural changes.99 Oncoproteins often mimics normal 
growth signals and make cancer cell growth independent of exogenous signals. The 
altered protein may be a growth factor receptor (e.g. HER2/neu, FGFR2), intracellular 
signal mediator (e.g. K-ras, AKT, PI3Kinase) or act as a transcription factor (e.g. 
Myc, ER, PR). Altering of intracellular signalling pathways (e.g. the SOS-Ras-Raf-
MAPK cascade and the PI3Kinase signalling pathway) enables a constitutive 
mitogenic signal even without sustained stimulation100, exemplified in figure 6. 
Figure 6 Illustration of growth signalling pathway; activated receptor tyrosine kinase  
signalling via Ras-Raf-MEK-ERK and via PI3K/AKT.  
PDK1: Phosphoinositide-dependent kinase 1, PIP3:phosphatidylinositol-3,4,5 triphosphate, PIP2: 
phosphoinositide-4,5 bisphosphate. 
Adapted from Krakstad and Chekeneya 2010.102
Genetic alterations in several oncogenes involved in the PI3Kinase signalling 
pathway have been described in endometrial cancer: 
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HER2/neu 
ERBB2/HER2/neu; Human Epidermal growth factor receptor 2, is an oncogenic 
truncated receptor firing without any ligand binding thus promoting cell growth, 
proliferation as well as hindering apoptosis via the PI3Kinase signalling pathway. 
This oncogene is known to be amplified and the receptor overexpressed in 20-25 % of 
breast cancers. The HER2 targeting monoclonal antibody trastuzumab has 
successfully been implemented in the clinic in adjuvant therapy and treatment of 
advanced or recurrent HER2 positive breast cancer.103, 104 In endometrial cancer this 
gene has been found to be amplified in 1 % of Type I endometrial cancer and 17% of 
Type II105, while overexpression of the protein as detected by immunohistochemistry 
is reported from 3-10% in Type I and 30-40% in Type II cancers.106, 107
K-ras 
K-ras is a G-protein (GTP-ase), controlling cell growth and differentiation. Although 
the Ras-pathway mostly is described to act via the Raf-MAPK cascade, Ras may also 
activate PI3Kinase and thus participate in the PI3Kinase signalling pathway.99 As an 
oncogene Ras may be activated by amplifications or point mutations, the latter has 
been identified in 10-30% of endometrial carcinomas.97, 108
PI3Kinase 
PI3Kinase is a lipid kinase that phosphorylates PIP2 to PIP3 which activates AKT and 
promotes proliferation, differentiation, motility, angiogenesis and avoidance of 
apoptosis.99, 109, 110 The PI3Kinase signalling pathway is the most frequently altered 
pathway in endometrial cancer.97 In human malignancies PI3K gain-of-function 
mutations are a frequent oncogenic event.111 In endometrial cancer, mutations in the 
PI3CA, coding for the catalytic subunit; PI3CA, is found in 30% of Type I cancers 
and 20 % of Type II, while PI3CA amplifications are seen in 2-14 % and 46% of 
Type I and Type II respectively.96, 97 However mutation of the regulatory unit PI3R1
has recently been described in 43% of Type I and 12% of Type II. This mutation also 
36
promotes phosphorylation of AKT, and thus activates the PI3Kinase signalling 
pathway.112
Stathmin  
Stathmin or oncoprotein-18 is a protein destabilizing microtubules, acting as an 
oncoprotein by promoting cell proliferation, mobility, metastasis and resistance to 
antimicrotubule chemotherapy.113, 114 Stathmin is inactivated by phosphorylation but 
the amount of protein is foremost regulated at the transcriptional level.115 A point 
mutation in the coding region of STMN1 has been described in oesophagus cancer 
cells.116, 117 The corresponding protein thus experimentally expressed showed 
decreased phosphorylation. Stathmin protein expression has been associated with 
PI3Kinase activity in breast and endometrial cancers.96, 118 The latter found STMN1 
overexpressed in 15% of Type I cancers compared to 64% for Type II.96
Other oncogenes have also been reported as altered in endometrial cancer; Drug 
sensitive mutations in the fibroblast growth factor receptor 2 (FGFR2) tyrosine kinase 
gene have been reported in 12% of endometrial carcinomas.119 Nuclear accumulation 
of -catenin (CTNNB1), only partially explained by mutations, is detected more 
frequently in Type I compared to Type II cancers.120
Growth differentiation factor-15 
Growth differentiation factor-15, formerly named as macrophage inhibitory cytokine-
1, placental bone morphogenetic protein, placental transforming growth factor-A,  
prostate derived factor and non steroidal anti-inflammatory drug (NSAID)-activated 
gene-1. GDF-15 is a distant member of the transforming growth factor-β superfamily. 
Gene expression is stimulated by tumour necrosis factor-α, interleukins and 
macrophage colony-stimulating factor and regulates cell cycle, proliferation, 
proliferation, differentiation and apoptosis.121, 122 Overexpression have been found in 
ovarian cancer123, prostate cancer, colorectal cancer and breast cancer124, but to our 
knowledge, has not earlier been described in endometrial cancer. 
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1.5.2 Tumour suppressor genes 
Tumour suppressor genes code for proteins inhibiting growth and tumour formation, 
acting as gatekeepers against external growth promoting signals (e.g. Retinoblastoma 
protein) as well as maintainers of the internal well-being of the cell (e.g. TP53). With 
inactivation of one allele (by mutation, deletion or promoter region methylation), 
normal protein production is sustained. Inactivation of both alleles is needed to lose 
the protective function leading to uncontrolled cell growth. Thus for tumour 
suppressor genes there is a recessive trait; two “hits” are needed to trigger 
carcinogenesis by affecting a tumour suppressor in accordance with Knudson’s two-
hit hypothesis.99  
PTEN  
PTEN encodes for the Phosphatase Tensin homologue phosphatase counteracting 
PI3Kinase by dephosphorylating PIP3 to PIP2. Inactivating PTEN will promote the 
PI3Kinase signalling pathway and thus promote cell proliferation, cell survival and 
angiogenesis, and hinder apoptosis.29, 99, 109
In endometrial cancer PTEN loss is mostly associated with Type I tumours (50-83%) 
and only 5-10% of Type II cancer, thus mostly related with a less aggressive 
phenotype and good prognosis.97, 125, 126
TP53  
The tumour suppressor gene TP53 encodes for a transcription factor responsible for 
guarding the genomic integrity. If errors in DNA replication are detected, TP53 
initiate cell cycle arrest, DNA repair or apoptosis. This is the most frequently mutated 
gene in human cancers, and is mutated in over 90% of Type II endometrial cancers 
compared to 20% of Type I.97, 108 TP53 is inactivated by ubiquitilation by MDM2, 
thus overexpression of MDM2 can also lead to reduced TP53 function. Normal TP53 
is rapidly degraded while non-functional mutant TP53 resists degradation. A 
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concordance of 76% between mutation and protein overexpression is reported in 
endometrial cancer.127
Other tumour suppressors of importance in endometrial cancer are p16 and E-
cadherin, loss of these are encountered in 83% and 5-50% of Type I cancers 
respectively and in 5 and 62-87% of Type II cancers.97, 128
1.5.3 Care-taker genes 
When DNA replications proceed incorrectly or other DNA damages occur, repair 
mechanisms are activated. The mismatch repair genes (MMR genes) initiate repair of 
DNA replication errors, inhibit recombination between un-identical DNA sequences 
and respond to DNA damage to hinder genetic instability.99 Autosomal germline 
mutations of MMR genes such as MLH1, MSH2, MSH6 and PMS2 are found in 
Lynch syndrome; hereditary non-polyposis colorectal cancer (HNPCC), where 
endometrial cancer is the commonest extra-colonic cancer in females characterized by 
microsattelite instable (MSI) tumours.26 In sporadic endometrial cancer methylation 
of MMR genes may lead to replication errors of microsatellites (simple repetitive 
DNA sequences) and microsatellite instability. MSI is prevalent in Type I cancers, 20-
45%, but rare in Type II (0-5%).97, 129
Another caretaker gene set is BRCA1 and BRCA2, responsible for repairing double 
strand DNA breaks. Germline mutations are seen in hereditary breast and ovarian 
cancers, but are seldom a cause of endometrial cancer.130, 131
DNA ploidy as a tumour marker 
Normal cells contain 46 chromosomes and are termed diploid. With either fewer or 
more than these 23 chromosome pairs, the cell is referred to as aneuploid. 
Carcinogenesis is often characterised by aberrant mitosis, chromosomal instability 
39
and loss of the protective TP53, thus aneuploidy is common in cancer cells.99 In 
endometrial cancer aneuploidy is present in around 20% of patients and associated 
with Type II cancers.132, 133
1.5.4 Tumour markers more specific related to endometrial cancer 
Hormone receptors 
The endometrium is highly hormone sensitive and express both estrogen and 
progesterone receptors. Normally the endogen ovarian produced estrogen induces 
endometrial proliferation. When progesterone is added in the second half of the 
menstrual cycle, the estrogen driven proliferation is antagonized and the epithelium 
differentiates from the proliferative to the secretory phase.134 Although both estrogen 
and progesterone receptor status is known to correlate with clinical features and 
prognosis in both endometrial and breast cancer, targeting the ER pathway yields 
partly different results for these cancers.135  
ER 
Hormone activated estrogen receptor, mostly the isoform ERα, is known to be 
important in endometrial carcinogenesis.  Acting as a transcription factor, ER bound 
to the estrogen response element (ERE) of target genes, can induce expression of 
growth factors (EGF, TGF-α) and growth factor receptors (ERBB1 and ERBB2, IGF-
I and IGF-II) known to stimulate both the PI3Kinase- and Ras/Raf pathways and thus 
stimulate mitogenic activity.15 ERα phosphorylated by AKT can lead to ligand 
independent response without estrogen coupled to the receptor, increased 
transcription of growth factors and stimulation of mitosis.15, 136 An alternative 
estrogen receptor GPER/GPR30 has been described and has been demonstrated to 
mediate estrogen stimulation and PI3Kinase activation in nuclear ER negative cells.137
Loss of ER is highly linked to type II endometrial cancer.138  
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PR 
PR is considered essential to inhibit estrogen induced hyperproliferation, and thus to 
counteract carcinogenesis. Both PR-A and PR-B are expressed in endometrial 
tissue134, but in endometrial cancer mostly PR-A is investigated and generally referred 
to as PR. Similarly to ER, PR loss is correlated with Type II cancers.138 Progestin 
effects are mainly mediated through PR, and in ER positive tumours progestin may 
yield an anti-estrogen effect.134 This treatment option is mainly considered as a 
possibility for young women with endometrioid low grade tumours where removal of 
the uterus is avoided to retain the possibility of child-bearing. 
In table 4, genetic abnormalities are investigated separately. In reality, tumours will 
exhibit multiple defects. Specific “clustering” of aberrations may affect different 
aspects of tumorigenesis.101 Upregulation of certain genes combined with 
downregulation of other sets of genes has been reported to be characteristic for 
activation of specific oncogenic pathways.147 The PI3Kinase signalling pathway is 
one such major pathway found to be upregulated in cancer in general, and in 
aggressive subtypes in particular.109, 110 Activation of this pathway may affect sets of 
genes (expression signature) that may be more robust in determining the involvement 
of the signalling pathway compared to the regulation of a single gene. One such 
expression signature of activated PI3Kinase has been reported by Gustafson148, 
another by Catasus.149 Integrated analyses of genome-wide expression and copy-
number data suggest that activation of this PI3Kinase signature is associated with 
amplification of PIK3CA region, aggressive phenotype and poor survival for 
endometrial carcinomas.96 Other genes active in regulation of this pathway are K-ras, 
HER2/neu, ER and PTEN. 
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Table 4 A summary of genetic alterations and their relevance for Type I versus Type 
II endometrial cancers. 
Target Function Alteration Type I (%) Type II (%) 
KRAS 97, 108 Oncogene Mutation 11-26 0-10 
ERBB2/HER-
2/neu   105-107 
Oncogene Amplification, 
expression 
1  17-80 
PIK3CA139 Oncogene Mutation 21-46 46 
PIK3CA96, 97 Oncogene Amplification 2-14 46 
Stathmin   Oncoprotein Overexpression 15  64 96
FGFR2119 Oncogene Mutation 12 12 
PTEN97, 125, 140 Tumour suppressor Mutation, deletion, 
methylation 
35-83 0-11 
TP5397, 108, 141 Tumour suppressor Mutation 5-20 80-93 
P1697, 142, 143 Tumour suppressor Mutation, 
methylation, 
expression 
8 5-45 
MSI129, 144 DNA repair Methylation, 
mutation 
20-45 0-5 
ER, PR138 Transcription 
factors 
Expression 70-73 19-24 
Beta-catenin   
120, 145 
Oncogene Mutation, 
expression 
18-47 0-5 
E-cadherin146 Tumour suppressor Mutation, 
methylation 
5-50 57-87 
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1.6 Biomarkers predicting prognosis in endometrial cancer 
A biomarker is a ”Characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention” as defined by the National Institute of Health 
Biomarkers Definitions Working Group.150 Thus, traditional clinical as well as 
histopathological features can be regarded as biomarkers. Regarding endometrial 
cancer, both age and nulliparity are noted as independent factors for survival.5, 151  
1.6.1  Clinicopathological characteristics as biomarkers 
FIGO (Federation of Gynaecology and Obstetrics) stage (table 5) is the strongest 
prognostic factors in endometrial cancer, with significantly reduction in disease-
specific survival with higher stages. 96% 5-year survival is reported for patients with 
localised tumour, 67% with regional- and 17% with distant metastasis.152
Corresponding figures using the recent revised FIGO 2009 classification is 90 and 
78%  respectively if tumour infiltrates inner- or outer half of the uterine wall (FIGO 
stage I), 74% if cervical stroma is involved (FIGO II), 56, 36, 57 and 49% 
respectively with adnexal, vaginal, pelvic lymph node or para-aortic lymph nodal 
involvement (FIGO III), and 22 and 21% respectively with bladder/rectal versus 
distant metastases.93
The impact of deep myometrial invasion on prognosis is illustrated by the significant 
difference in survival between FIGO IA (<50%) and FIGO IB (>50%), but is also a 
risk factor for advanced stage including lymph node metastasis and identified as an 
independent risk factor for poor survival even in high stage disease.153-155  
Metastatic lymph nodes, either pelvic (FIGO IIIC1) or para-aortic (FIGO IIIC2) are 
an independent predictor of poor survival. Even when adjusted for uterine risk factors 
as high histologic grade, cervical stromal invasion or myometrial infiltration >50%, a 
large study of nearly 27 000 lymph node sampled patients from the American SEER 
registry, found patients with metastatic lymph nodes to have significantly lower 
disease-specific and overall survival than patients with negative lymph nodes.153  
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Table 5 Surgical tumour classification according to the International Federation of 
Obstetrics and Gynaecology (FIGO) originally from 1988, revised 2009. 
Stage FIGO 198862 FIGO 200964 
I IA Tumour limited to endometrium IA Tumour with no or less than 
half myometrial invasion 
 IB Invasion to <1/2 myometrium  
 IC Invasion  >1/2  myometrium IB Invasion equal to or more than 
half of the myometrium 
II IIA Endocervical glandular 
involvement only 
II Tumour invades cervical stroma 
but does not extend beyond the 
uterus 
 IIB Cervical stromal invasion  
III IIIA Tumour invades serosa and/or 
adnexae and/or positive peritoneal 
cytology 
IIIA Tumour invades the serosa of 
the corpus uteri and/or adnexae  
 IIIB Vaginal metastases IIIB Vaginal and/or parametrial 
involvement 
 IIIC Metastases to pelvic and/or para-
aortic lymph nodes 
IIIC1 Metastases to pelvic nodes 
  IIIC2 Metastases to para-aortic 
lymph nodes with or without 
positive pelvic lymph nodes 
IV IVA Tumour invasion of bladder and/or 
bowel mucosa  
IVA Tumour invasion of bladder 
and/or bowel mucosa 
 IVB Distant metastases including intra-
abdominal metastases and/or inguinal 
lymph nodes 
IVB Distant metastases including 
intra-abdominal metastases and/or 
inguinal lymph nodes 
62Creasman: Gynecol Oncol;35:125-7   64Pecorelli: Int J Gynecol Obstet 2009;105(2):103-4 
 
Using patients with metastatic nodes but no uterine risk factors as reference category, 
patients without metastatic nodes had a hazard ratio of 0.09 (95% CI 0.07-0.11) for 
disease-specific death and 92% 5-year survival if no uterine risk factors were present 
compared to a hazard ratio of 0.64 (95%CI 0.52-0.79) and 69% 5-year survival with > 
2 uterine risk factors. Within the group of lymph node positive patients, having any 
additional uterine risk factors increased the risk with HR 1.24 (95% CI 1.02-1.52) and 
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with a 58% 5-year survival compared to 68% for lymph node positive without 
additional uterine risk factors. Although detection of lymph node metastases is a well 
established prognostic factor, randomised controlled trials have not shown any 
definitive survival benefit from the performance of lymphadenectomy in patients with 
presumed FIGO stage I disease.80 It is an ongoing challenge to properly identify 
patients with high risk of lymph node metastasis that may benefit from adequate 
lymph node sampling and to avoid potential side effect from lymphadenectomy for 
those who most likely have no benefit from the procedure. 
Histological type and grade are also strong predictors of outcome: Non-endometrioid 
subtypes including serous papillary, clear cell and undifferentiated carcinomas as well 
as carcinosarcoma have significantly poorer outcome than endometrioid tumours. The 
non-endometrioid tumours are all classified as high-grade tumours. Within the 
endometrioid subgroup, low-grade, well differentiated tumours have significantly 
better survival than undifferentiated high grade cancers.49, 70 Most tumours are 
endometrioid but the proportion of non-endometrioid tumours increase with increased 
stage; from 8% of Stage I-II to 21% of stage III-IV patients. Within Stage I disease, 
patients with endometrioid histology had a 5-year overall survival of 90-93%, while 
corresponding figures for   non-endometrioid tumours were 78-85%. Also the 
proportion of high-grade endometrioid tumours is increased with higher stages. 
Within Stage I disease, Grade 2 tumours had reduced survival with HR 1.4 (95% CI 
1.1-1.7) and Grade 3 HR 2.8 (95% CI 2.2-3.6) compared to Grade 1 tumours.49  
These two distinct different prognostic groups; endometrioid estrogen driven versus 
non-endometrioid, have also been categorised as Type I and Type II respectively.12, 14
Although there is considerable overlap, they also show different molecular 
characteristics as summarised in table 4. 
Several studies have demonstrated that involvement of blood vessels156, 157 or 
lymphovascular space is linked to poor outcomes, emphasizing the importance of 
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reporting this information in the routine histopathological reports for endometrial 
carcinomas.158, 159
1.6.2  Molecular biomarkers 
Molecular biomarkers comprises evaluation by genomic or proteomic techniques. 
Proteomics includes investigations of proteins; often by specific protein targeted 
antibodies in immunohistochemical investigations. 
There is a large range of genomic approaches for genetic investigations: abnormal 
number of chromosomes can be detected by DNA ploidy analyses, specific mutations 
can be identified by sequencing and gene copy number alterations by SNP array. Gene 
expression can be evaluated by microarray or quantitative PCR. These methods are 
illustrated in figure 7 in relation to assessment of alterations on DNA, mRNA or 
protein levels. 
Figure 7 Illustration of different methods identifying genetic aberrations at the DNA, 
mRNA and protein levels. 
Immunohistochemical (IHC) analyses in addition to Haematoxylin-Eosin stainings are 
performed in most pathology laboratories. In some diagnostic work-ups this is 
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performed routinely, such as HER2 testing in breast cancer.160 IHC analyses are 
mainly less costly and simpler to perform than genetic analyses. Due to the 
applicability in routinely available formalin fixed paraffin embedded tissue, a 
biomarker with good correlation assessed by IHC will often be preferred to genomic 
approaches, if similar prognostic and predictive information can be derived. 
For endometrial cancer, biomarkers have been most extensively studied in 
hysterectomy specimens, but for some markers also in preoperatively collected 
curettage samples. A summary of the most common IHC markers and their respective 
impact on survival is summarised in table 6. Based on a convincing number of 
sufficiently powered studies with robust outcome data, DNA ploidy, ER, PR and 
TP53 status seem to contribute independent prognostic information adjusted for 
standard histopathological data132, 138, 161, although the additional prognostic impact of 
biomarkers in patient series subjected to lymphadenectomy has to date been less 
studied. 
Biomarkers applied on preoperative biopsies or curettage specimens give the 
additional possibility to improve the identification of patients with aggressive disease 
and poor prognosis prior to surgery. Even when adjusting for FIGO stage and 
histological type and grade, several investigations have demonstrated independent 
prognostic value of hormone receptors, TP53 and p16 while neither HER2 nor ploidy 
had independent significance when estimated in preoperative endometrial biopsies. 
Preoperatively biomarkers in the assessment of risk for lymph node metastasis have 
been addressed by Mariani in 2005 through a retrospective case-control analysis of 82 
patients. They found TP53 tested in curettage specimen as an independent predictor of 
metastatic lymph nodes adjusted for histologic subtype.65  
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Table 6 Biomarkers and their reported reduction (%) in survival when tested in 
hysterectomy or preoperative specimens. 
Biomarker Hysterectomy 
specimens 
Preoperative 
biopsy 
Loss of ER-PR expression 
Orescovic-04162 
Engelsen-08138 
 
Not specified 
31% 
 
35% n.s Cox 
30% 
High expression of TP53  
Salvesen-99161 
Mariani-00163 
Silvermann-00164 
Engelsen-06143  
Oreskovic162 
 
30% 
 
 
 
Not specified 
 
 
33% 
21% Cox n.a. 
33% 
30% 
Loss of P16 expression  
Salvesen-00142 
Engelsen-06143 
 
34% 
 
 
35% 
High proliferation rate (Ki-67)  
Salvesen-99161 
Engelsen-08106 
 
26% 
16% 
 
 
13% n.s Cox 
High expression of Stathmin  
Salvesen-0996 
 
18% 
 
Overexpression of Her2NEU  
Morrison -06 107 
Mariani-00163 
Engelsen-08106 
 
42% 
 
20% n.s Cox 
 
 
18% n.s.Cox 
20% n.s Cox 
Aneuploidy 
Mariani-00163 
Silverman-00164 
Wik-09132 
 
 
 
19% 
 
12% n.s Cox 
27% n.s. Cox 
 
n.s: not an independent marker in multivariate Cox analyses when adjusted for FIGO 
stage, histologic type or grade n.a: not accounted for 
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CA-125 measurements have been suggested as a predictor for lymph node metastasis 
but neither optimal cut-off nor which supplementary analyses to use in combination in 
a prediction algorithm have been defined.53, 56 Thus, there is no established serologic 
analyses in general clinical use to predict lymph node metastasis or poor outcome in 
endometrial cancer. 165
1.6.3  Prognostic value from specific genomic analyses  
Most studies of genetic aberrations in endometrial cancers have focused on the 
distinction between Type I and Type II cancers. Also, an approach to further 
molecularly classify tumours based on histological subtypes has often been applied. 
Many of these studies have been selective and too small for adequate survival 
analyses, sometimes generating conflicting data regarding prognosis. Of the studies 
referred to in Table 4, neither has proven any independent survival effect for the 
investigated genomic marker.  In Morrison’s investigation of HER-2 amplification 
and expression these were not independent predictors of poor survival unless both 
factors were pathologic, with a HR of 2.30, 95% CI 1.25-5.32. The PI3CA
amplification in Salvesen’s series of 74 endometrial cancers was highly significantly 
associated with poor outcome in univariate analysis of recurrence-free survival, but 
not in multivariate analyses. However, the protein expression of Stathmin as a marker 
of the PI3Kinase pathway, had a HR of 2.14, 95% CI 1.28-3.59 in multivariate 
analysis when investigated in a larger patient series of 313 endometrial cancers.96
1.6.4  Predictive markers for therapy response 
Hormone receptor status in tumours has been linked to the effect of antihormonal 
therapy. In one study of patients with metastatic tumours treated continuously with 
tamoxifen and intermittently with weekly medroxyprogesterone acetate (GOG 119 
Study), patients with metastasis staining positive for ER showed significantly better 
response and overall survival. No correlation with PR and clinical response was 
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noted.95 A systematic review from 2007 found no randomized trails based on 
hormone receptors status but five cohort studies evaluating different regimens; 
hydroxyprogesterone caproate, megestrol acetate, letrozole and arzoxifene. All studies 
showed higher response rates in ER+ and PR+ tumours compared to tumours with 
receptor loss.166  
Contrasting breast, lung and colorectal cancers, none of the new targeted therapeutics 
has reached the clinic yet for endometrial cancers.97 In clinical trials for endometrial 
cancer, drugs targeting the PI3Kinase/AKT/mTOR pathway, EGFR/HER2 or VEGFR 
are being evaluated as summarised in Table 3. Since PTEN mutations and loss of 
function is common in endometrial cancer, and promotes the PI3Kinase/mTOR 
signalling pathway activation, PTEN staining by immunohistochemistry has been 
tested as predictor for response to mTOR inhibitors, but has not so far been shown to 
be applicable as predictive marker for response.97 Immunohistochemical staining for 
Stathmin, a surrogate marker for PI3Kinase activation, has also been suggested as an 
alternative marker to explore for prediction of response to PI3Kinase/AKT/mTOR 
inhibition.96 Vascular proliferation and microvessel density associates with outcome 
in endometrial cancer167, and vascular proliferation correlates with VEGF-A
expression. Thus, such markers for activated angiogenesis have been suggested as 
potential markers for response to angiogenesis inhibitors, but are yet to be evaluated. 
HER2 amplification is less frequent in endometrial compared to breast cancer and has 
not been as successful in predicting effect from trastuzumab therapy as for breast 
cancer. The molecularly based trial targeting both EGFR and HER-2 (NCT00748709) 
based on HER2 and/or EGFR amplification or mutation status, was one of the first 
target-specified patient inclusion phase II trials for endometrial cancer.97
50
2.  Aims of the study 
2.1 Background 
Although endometrial cancer in general has a good prognosis, 15-20% recurs.5
Surgery is the main component of treatment with lymph node sampling increasingly 
advocated as compulsory for complete staging. In metastatic disease there has been 
limited effect from conventional chemotherapy or antihormonal treatment, and no 
novel targeted therapies are yet available for this patient group.  Thus, improved 
identification of high-risk patients and more effective and individualised therapy, 
surgical as well as systemic, is urgently needed. Several biomarkers including 
hormone receptor status, TP53 and Stathmin expression have been found to be of 
prognostic importance in retrospective studies. The PI3Kinase signalling pathway is 
one of the major upregulated oncogenic pathways and has been documented to be 
over-expressed in aggressive endometrial carcinomas with poor prognosis.96
PI3kinase inhibitors as cancer treatment are now entering clinical trials. 
2.2 General aims 
The general aim was to evaluate if biomarkers tested preoperatively could identify 
aggressive endometrial carcinomas; patients with advanced disease at primary 
treatment, especially lymph node metastasis, and patients with poor survival. A 
second aim has been to focus on potentially targetable biomarkers for hormone 
receptor status and PI3kinase activation, to identify markers potentially applicable as 
predictive markers for selecting patients for treatment with antihormonal therapy and 
PI3Kinase-inhibitors. Also, we wanted to elucidate changes in treatment strategy and 
survival for endometrial carcinoma patients during a 30 year period in a population 
based setting. 
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2.3 Specific aims 
1. To explore potential markers for PI3kinase activation: Investigate the 
immunohistochemical markers AKT, Phospho-AKT and Stathmin in relation to 
clinico-pathological variables and patient prognosis; to examine whether these 
markers reflects the level of PI3Kinase activation based on mRNA expression levels 
(Paper I).  
2. To validate the prognostic value of Stathmin immunohistochemical expression 
in a large prospective multicenter setting; to test if Stathmin expression in 
preoperative curettage samples can predict lymph node metastasis (Paper II). 
3. To investigate and validate in two independent patient cohorts if the expression 
level of growth differentiation factor-15 (GDF-15) in preoperative blood plasma 
samples correlated to clinico-pathological patient characteristics and prognosis and 
whether GDF-15 could predict lymph node metastasis (Paper III). 
4.  To validate the prognostic value of the immunohistochemical expression of 
Estrogen Receptor (ER), Progesterone Receptor (PR) and TP53 in preoperative 
curettage specimen and to investigate if these markers could improve prediction of 
lymph node metastasis in a large prospective multicenter setting (Paper IV). 
5. To investigate if changes in clinico-pathological patient characteristics and 
therapeutic strategies including increased frequency of lymph node sampling are 
reflected in survival changes through careful characterization of a 30-years population 
based cohort (Paper V). 
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3. Materials 
3.1 Patient series 
This study has used several patient series in the various papers, summarised in figure 
8. 
3.1.1 The Hordaland cohort: 
To evaluate changes over time, both in underlying tumour and patient characteristic as 
well as treatment strategies (Paper V), a stringent population based cohort of patients 
from Hordaland treated during 30 years at Haukeland University hospital has been 
selected.  
Haukeland University Hospital is a tertiary cancer centre responsible for treatment of 
women with gynaecological cancer primarily from Hordaland County but is also a 
referral centre for Rogaland and Sogn og Fjordane Counties. To avoid over-
representation of high-risk cases, aiming for a representative population based cohort 
from our region in Norway, we have collected only endometrial carcinoma patients 
with verified permanent address in Hordaland County at time of primary treatment.  
The first decade (1981-1990), 286 patients, have been extensively studied and 
described in several earlier publications.120, 142, 143, 168, 169 Cross-checking with data 
from the mandatory Cancer Registry of Norway has confirmed that 286 of 303 
patients (94%) from Hordaland with histological verified endometrial carcinoma had 
been correctly identified and included in our study cohort through the hospital 
diagnosis registries at the Departments of Pathology as well as Gynaecology and 
Obstetrics. The middle decade (1991-2000) was retrospectively collected by a similar 
approach, containing 307 patients, whiles the last decade (2001-2010) 484 patients, 
was prospectively included as part of the MoMaTEC trial 
(http://www.clinicaltrials.gov/ct2/show/NCT00598845). 
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Figure 8 Patient cohorts which have been used in this thesis. A Number of patients in 
each series related to year of primary treatment and inclusion area. B Number of 
patients and cohorts used for each of the papers (Paper I-V) in this thesis.   
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Clinical data regarding age at primary operation, parity, menopausal status, height and 
body weight, date and type of primary and adjuvant treatment, histopathological type 
and grade, FIGO stage, lymph node sampling status and the course of disease were 
collected from patients’ medical records. Supplementary information was collected 
from primary physicians and private gynaecologists responsible for out-patient 
follow-up. Data from the two last decades were, similarly to the first cohort, cross-
checked for permanent address and diagnosis confirmation through the mandatory 
Norwegian Cancer Registry and the dates and causes of deaths were authenticated 
through the Norwegian Death Registry. 
Hordaland County is a region comprising 9.8 % of the total 4 920 000 Norwegian 
population being demographically well defined.170 The age-adjusted incidence rate of 
cancer in the corpus uteri (ICD-10 code C54) is similar in Hordaland as in total of 
Norway and has risen in parallel with a national increase since the initiation of 
national cancer registration in 1952.2 The Hordaland cohort collected during our study 
thus is assumed to be representative of a general Norwegian endometrial cancer 
population. 
The whole 30-years Hordaland cohort is investigated in Paper V, the 1981-90 
decennium and the first 76 consecutive patients enrolled in the 2001-10 cohort 
comprise the study population in Paper I. 
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Table 7 Comparison of distribution of patient characteristics between the large 
retrospective 1981-90 cohort and smaller prospective series from 2001 onwards 
from Hordaland studied in Paper I support that there are no significant differences 
between the cohorts. 
Variable Hordaland       
1981-1990 
Retrospective 
n=286 
Hordaland    
2001-2002 
Prospective  
n=76 
P-value1
Mean age years (Range) 65 (33-92) 66 (39-91) 0.6 
FIGO 19882  
   I-II 230 (78) 64 (22) 
0.5 
   III-IV 55 (82) 12 (18)  
Histological type 
   Endometrioid 257 (80) 66 (20) 
0.5 
   Non-endometrioid 29 (74) 10 (26)  
Histological differentiation 
  Grade 1-2 227 (80) 56 (20) 
0.3 
  Grade 3 59 (75) 20 (25)  
Myometrial infiltration3
   <50% 146 (80) 37 (20) 
0.1 
    >50% 90 (71) 36 (29)  
BMI(kg/m2) 4
    <25  103 (88) 14 (12) 
0.2 
   >25 112 (82) 25 (18)  
1t-test used for comparing age, all other correlations tested by Chi-Square test        
2 FIGO missing for 1 case in retrospective series                                                            
3 Myometrial infiltration available for 215 women                                                   
4BMI available for 215 cases in retrospective and 39 in prospective series 
3.1.2 Patients treated at Haukeland University Hospital not in the 
Hordaland cohort 
This patient series consists of 130 women treated at Haukeland University Hospital 
with permanent address registered being outside Hordaland County or with a 
histological diagnosis of carcinosarcoma. In addition to the Hordaland 2001-2010 
cohort these women were studied in the complete hospital based cohort treated at 
Haukeland University Hospital during the 2001-2010 decade.  
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The reason for not including carcinosarcomas in the analyses of the population based 
Hordaland cohort from 1981-2010 was that this histologic subtype was not available 
for the first part of the period studied. When the 1981-90 Hordaland cohort was 
collected, carcinosarcoma was not considered an entity classified as endometrial 
carcinomas but as sarcomas and thus not included in the population based cohort. 
During later years these tumours have increasingly been treated and classified as 
endometrial carcinomas171, in line with national guidelines.40
Identification of cases and registration of clinical data was otherwise similar for the 
Haukeland University Hospital and the Hordaland Cohorts. 
3.1.3 MoMaTEC trial 
Molecular Markers in Treatment of Endometrial Cancer 
http://www.clinicaltrials.gov/ct2/show/NCT00598845 is a prospective study initiated 
at Haukeland University Hospital in 2001 including the 614 patients 
(Hordaland/Haukeland University Hospital) as described above, and from 2007 
expanded with 9 centres actively recruiting additional 578 women; seven Norwegian 
hospitals (n=330) one Swedish- (n=109) and one Belgian comprehensive cancer 
centre (n=139). Patients primarily treated for verified endometrial carcinoma, 
including carcinosarcomas, were eligible for inclusion. In addition to the same 
clinico-pathological data collected for the Hordaland cohort, the histopathologic 
diagnosis from the routine preoperative biopsy or curettage histology reports available 
for 1166 patients, were classified as low risk versus high risk, the latter including all 
endometrioid grade 3, serous papillary, clear cell, carcinosarcoma and 
undifferentiated subtypes. This was in line with the study objective to evaluate 
prospectively a panel of biomarkers in relation to the standard pre- and postoperative 
clinicopathologic variables derived in a routine setting representing daily clinical 
practice. See Appendix for copy of inclusion and follow-up forms. Initially the FIGO 
1988 classification was used. When this was changed in 2009 the registration forms 
were updated and data reclassified accordingly.  
57
Compared with the other secondary Norwegian centres, the tertiary centres 
(Sahlgrenska, Leuven and Haukeland) enrolled significantly more high-risk patients 
with non-endometrioid histological subtypes, grade 3 differentiation, and advanced 
FIGO-stage as shown in Table 8. This is in line with the referral policies in the region 
studied. 
In Paper II all patients enrolled in the MoMaTEC study until end of 2009 was 
investigated and Paper IV contains all patients enrolled through 2010. 
Table 8 Characteristics for 1192 endometrial cancer MoMaTEC* trial patients at 
time of primary treatment related to including centre classified into three groups. P-
values are based on Pearson’s chi-square test.
Characteristics Haukeland    
n (%)  
Norwegian 
Other n (%) 
European 
Other n (%) 
P-value 
Age 
     <66 years 
     >66years 
314 (51) 
300 (49) 
166 (50) 
164 (50) 
101 (41) 
147 (59) 
0.017 
Menopausal status 
     Pre-/perimenopausal 
     Postmenopausal 
72 (12) 
542 (88) 
32 (10) 
298 (90) 
16 (7) 
232 (94) 
0.064 
FIGO 2009 classification  
     Stage I-II 
     Stage III-IV 
507 (83) 
107 (17) 
293 (89) 
37 (11) 
203 (82) 
45 (18) 
0.024 
Histological subtype 
     Endometrioid 
     Non-endometrioid 
489 (79) 
128 (21) 
286 (87) 
44 (13) 
195 (79) 
53 (21) 
0.010 
Histological differentiation1
     Grade 1-2 
     Grade 3 
395 (65) 
213 (35) 
250 (76) 
78 (24) 
167 (67) 
81 (33) 
0.002 
1Missing information about grade in 10 cases 
3.1.4 The Oslo cohort 
This is a sample of women treated for primary endometrial cancer at Oslo University 
Hospital Ullevaal during 2004-2009 with available preoperative plasma samples. This 
cohort was used as a primary investigation cohort evaluating the serological marker 
GDF-15 in the study applying plasma from 466 women with endometrial carcinomas 
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recruited from 2001-2010 at Haukeland University Hospital as validation cohort. 
(Paper III). The Ullevaal cohort had similar age and stage as those from Haukeland 
but with more differentiated tumours (p=0.03). 
3.2. Treatment and follow-up 
The main treatment component in endometrial cancer is surgical therapy including 
hysterectomy and bilateral salpingo-oophorectomy. If tumour infiltrates the cervix 
(FIGO stage II) radical hysterectomy with more extensive resection of 
parametrial/paracervical structures is performed (Wertheim-Meigs procedure).  
Lymph node sampling along pelvic vessels has increasingly been recommended as 
part of complete staging and lately even para-aortic sampling for high-risk groups has 
become customary in many centres. During 1981-1990 systematic lymph node 
sampling was not routinely done in Norway, and only suspiciously enlarged nodes 
were biopsied. From 1997 pelvic lymph node sampling was formally recommended 
by the Norwegian gynaecological oncology guidelines.89 Patients not suitable for 
surgical treatment have been staged by clinical examination, curettage and x-ray/CT-
scan results and offered external radiotherapy and/or uterine brachytherapy. 
Adjuvant radiation therapy was routinely recommended during 1981-2000; 
intravaginally if myometrial infiltration less than 50%, external pelvic radiation (45-
50GY) if deeper infiltrating or poorly differentiated tumours. From 2001 vaginal 
radiation (brachytherapy) was no longer routinely offered as adjuvant treatment, and 
external pelvic radiation was restricted to deeply infiltrating poorly differentiated 
tumours, aneuploid or non-endometrioid tumours. During this last period, 
chemotherapy has been increasingly offered as alternative to radiation therapy. 
Patients from Sweden or Belgium were offered significantly more adjuvant radiation 
therapy for stage I and II, compared to Norwegian patients as shown in table 9. 
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Patients without residual tumour have been followed by gynaecologists either at the 
hospital responsible for primary treatment or by gynaecologists in private practice. 
The standard follow-up protocol has been 3-4 visits first year, two the second and 
yearly thereafter for five years. In addition to gynaecological examination, cytological 
smear from the vaginal vault was performed in patient not treated with radiotherapy, 
and for most yearly chest x-rays have been performed.  
Table 9 Treatment given to 1192 endometrial cancer patients included in the 
MoMaTEC trial related to centre for primary treatment classified as three groups. P-
values are based on Pearson’s chi-square test.
Characteristics Haukeland     
n (%)  
Norwegian 
Other n (%)
European 
Other n (%)
P-value
Lymph node sampling 
     Performed 
     Not performed 
474 (77) 
140 (23) 
257 (78) 
73 (22) 
125 (50) 
123 (50) 
<0.001 
Lymph nodes removed 
     < 10 
     > 10 
130 (28) 
343 (73) 
85 (33) 
171 (67) 
12 (10) 
111 (90) 
<0.001 
Adjuvant primary treatment 
     FIGO Ia   
               no 
               any1 
     FIGO Ib/II  
                no 
                any2
     FIGO III/IV  
                no 
                any 
317 (94) 
20 (6) 
100 (67) 
52 (34) 
13 (15) 
76 (85) 
177 (93) 
14 (7) 
59 (59) 
41 (41) 
5 (14) 
31 (86) 
103 (72) 
41 (29) 
23 (39) 
36 (61) 
3 (8) 
35 (92) 
<0.001 
0.002 
0.574 
1Radiotherapy for 1/34 patients in Norwegian and 33/41 in non-Norwegian centres 
2Radiotherapy for 49/93 in Norwegian and 35/36 in non-Norwegian centres 
Patients were urged to take contact in between scheduled appointments if symptoms 
of recurrence (vaginal bleeding) occurred. Individual follow-up regimens were 
constructed for patients not radically treated. 
Date of last follow-up was June 15th 2011 for the Hordaland Cohorts with a mean 
follow-up time for survivors of 17.5, 9.7 and 3.5 years for the three respective 
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decades studied and a mean for all patients 7.5 years (range 0.1-23.2). 191 patients 
died from endometrial cancer during the follow-up period. 
For the MoMaTEC patients, the date of last follow-up was February 15th 2011, with 
mean follow-up time for survivors 32 months, range 0-96. 119 patients died from 
endometrial cancer during follow-up period. 
3.3   Clinical and histopathological variables 
Clinical data such as patient age, parity, menopausal status, height and weight at time 
of admission for primary treatment, as well as date and type of primary therapy was 
recorded. Also treatment of recurrent or progressive disease, location and time of 
recurrence and date and status of last follow-up including cause of death if deceased, 
were retrieved from patient records. Histopathological diagnosis and myometrial 
infiltration were retrieved from the routine pathological reports for final hysterectomy 
specimens, for the 1991-2010 Hordaland cohort and all MoMaTEC patients’ 
preoperative biopsy/curettage report were also collected. During the 1981-1990 
period, routine histology at Haukeland did not consistently include differentiation nor 
subtypes for endometrial carcinomas, and for these patients the histopathological 
features have earlier been revised according to the WHO criteria.172 Vascular invasion 
was classified as present if invasion in more than one vessel or vascular space was 
seen. Upper quartile of mitotic count pr high power field (x400) hot spot area was 
classified as high, corresponding to >17 mitosis.  
Myometrial infiltration was measured as the distance tumour invaded the uterine wall 
and recorded as either less than or equal or more than half of the myometrial 
thickness. 
Ploidy analyses comprising the ratio of aneuploid DNA content to the amount of 
normal diploid cells were measured in primary tumours from hysterectomy specimens 
and were available for 566 patients from the Haukeland series. 
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Patients were originally staged according to FIGO 1988 criteria62, and this was used 
in Paper I-III and Paper V. In 2009 the FIGO classification was officially 
changed.63, 64 In the revised classification former IIA (tumour spread in cervical 
mucosa/glands) was classified as stage I according to depth of myometrial infiltration: 
IA if less than 50%, IB if equal or deeper than 50%. Positive abdominal cytology 
without any other metastatic lesions was no longer classified as IIIA. In addition IIIC 
(former: metastatic pelvic lymph nodes) were expanded as IIIC1: pelvic lymph nodes 
and IIIC2 para-aortic lymph nodes, summarised in table 5. For the ongoing 
MoMaTEC trial patients have been reclassified according to the FIGO 2009 criteria 
and used in Paper IV. For comparison see table 10. 
Table 10 Comparison of 5-year survival for FIGO stages according to 1988 and 2009 
criteria in the MoMaTEC cohort of 1192 patients. 
Variable FIGO 1988           
n (%) 
5-years survival FIGO 2009          
n (%) 
5-years 
survival 
FIGO I 876 (74) 93% 919 (77) 93% 
FIGO II 112 (9) 85% 84 (7) 80% 
FIGO III 147 (12) 58% 133 (11) 55% 
FIGO IV 571 (5) 19% 56 (5) 19% 
1One case with enlarged para-aortic metastasis originally classified as FIGO IVB 
changed to IIIC2
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4. Methods 
Formalin fixed paraffin embedded (FFPE) tumour tissue from both preoperative 
curettage and hysterectomy specimens have been collected and applied for 
immunohistochemical studies. Freshly frozen primary tumours from hysterectomy 
specimens were applied in the mRNA microarray investigations. Plasma samples 
were applied in immunoassay analyses. An overview of specimens applied and 
biomarkers studied in the different papers is given in figure 9 and table 11. 
Figure 9 Overview of types tissues sampled, analyses performed and outcome 
studied.  
A Blood samples B Curettage/preoperative biopsy C Hysterectomy tissue from 
operation D Plasma protein analysis E Immunohistochemistry F mRNA microarray G
Clinicopathological features including lymph node metastases H Survival I Death 
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Table 11 Overview of the various patient series, specimen types, methods applied and biomarkers 
investigated in the different papers. 
Article Patient 
cohort 
n=patients 
Tissue  
specimens 
Tissue 
preparation 
Biomarker  Method Number 
specimen 
with 
evaluable 
data 
Paper I Hordaland 
1981-1990 
n=286 
Hysterectomy 
 
 
Curettage 
FFPE/ 
TMA1 
Stathmin 
AKT 
pAKT 
Stathmin 
IHC2 
 
241 
245 
228 
175 
 Hordaland 
2001-2002 
n=76 
Hysterectomy  
 
 
Freshly 
frozen 
Stathmin 
AKT 
pAKT 
PI3Kinase- 
Score 
IHC 
 
 
mRNA 
MicroArray 
70 
69 
70 
76 
Paper II MoMaTEC
2001-2009 
n=1076 
Hysterectomy 
Curettage 
FFPE/ TMA  Stathmin 
Stathmin 
IHC 477 
818 
Paper III Haukeland
2001-2009 
n=564 
Blood plasma Freshly 
frozen 
GDF-15 Immuno-
Assay 
 
466 
 Ullevål Blood plasma  GDF-15  44 
Paper IV MoMaTEC 
2001-2010 
n=1192 
Curettage FFPE/ TMA ER, PR, TP53 IHC 841 
Paper V Hordaland
1981-2010 
n=1077 
Clinico-
pathological 
data only 
- - - - 
1FFPE: Formalin Fixed Embedded Paraffin, TMA: Tissue Micro Array 2IHC: Immunohistochemistry 
 
4.1 Tissue MicroArray (TMA) 
To gain high profile output and efficient investigation of the large number of samples 
derived from these patient cohorts, three 0.6 mm cylinder biopsies from each 
individual tumour specimen were transferred from the donor to a recipient block. A 
representative area of tumour of highest grade based on evaluation of haematoxylin 
and eosin stained slides were selected and punched out by using a custom made 
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precision instrument (Beecher Instrument, Silver Spring, MD, USA). These biopsies 
where mounted in recipient paraffin blocks and 5 μm sections prepared for 
subsequent immunohistochemical stainings. This method of producing tissue 
microarrays (TMA) have been described and validated in several studies.138, 173, 174
While curettage samples were collected from all centres participating in the 
MoMaTEC trial, TMAs from hysterectomy specimens were only generated in parallel 
for Haukeland patients. As shown in table 12, patients with inadequate tissue samples 
in the TMAs prepared from the curettage specimens, more often had non-
endometrioid histological type and high histological grade, otherwise patient 
characteristics, including survival, were similar. 
Table 12 Comparison of patient- and histopathologic characteristics according to 
availability of tumour tissue in TMAs for the 1192 MoMaTEC trial patients. Cases 
with representative tumour tissue from curettage available in TMAs were further 
studied by immunohistochemistry for potential biomarkers.
Characteristics IHC    not 
performed      
n (%) 
IHC 
performed 
n (%) 
P-value 
Age  >66years 152 (52) 459 (51) 0.8 
Para >11 239 (84) 744 (84) 1.0 
Postmenopausal 261 (89) 811 (90) 0.6 
BMI >25.0(kg/m2)2 119 (62) 253 (64) 0.7 
Myometrial infiltration >50%3 78 (29) 270 (34) 0.1 
FIGO 2009 stage III/IV 47 (16) 142 (16) 0.9 
Curettage histology non-endometrioid4 78 (28) 128 (14) <0.001 
Curettage differentiation grade 34 102 (36) 211 (24) <0.001 
Hysterectomy histology non-endometrioid  78 (27) 147 (16) <0.001 
Hysterectomy differentiation grade 35 112 (39) 260 (29) 0.002 
Primary surgery curettage or debulking 15 (5) 30 (3) 0.1 
Lymph node sampling not performed 90 (31) 246 (27) 0.3 
Metastatic lymph nodes 22 (11) 83 (13) 0.5 
Missing data 121 for parity, 2602 for BMI, 3136 for myometrial infiltration, 426 for 
curettage histology and differentiation, 58 for hysterectomy differentiation 
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4.2 Immunohistochemistry 
Thin slides (5 μm) cut from TMA blocs made as described above were dewaxed with 
xylene/ethanol before antigen retrieval by microwaves and after peroxidase block 
(S2032 Dako Cytomation) incubated with antibodies according to optimized protocols 
as summarised in table 13. Tissue samples known to express the individual antibody 
were added as positive controls while omitting the primary antibody and using diluent 
only was used as negative control. The staining procedures were either done manually 
(AKT, Phospho-AKT and Stathmin in Paper I), or by using the DAKO Autostainer 
(no. 3400-9567) automated slide-processing equipment as described by the 
manufacturer (for Stathmin in Paper II and ER, PR and TP53 in Paper IV). The 
detection system used was EnVision+(K4006) DacoCytomation, with the enzyme 
labelled polymer of secondary antibody and DAB+ chromogen. Slides were finally 
counterstained with Haematoxylin (Dako S2020). For ER, PR and TP53 the protocols 
published earlier138, 143, have been utterly refined and Stathmin staining was tested out 
and optimised under guidance and collaboration with the technician (G.L.H) and the 
senior pathologist (L.A.A). 
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Table 13 Survey of antibodies and immunohistochemical staining protocols used in this study. 
Biomarker 
Protein 
targeted 
Antigen  
retrieval: 
Microwave 
Primary 
antibody Provider Dilution Incubation Detection 
Cell cycle  
regulator Stathmin 
10 min 750W 
15 min 350W 
Citrate pH 6 #3352 
Cell 
Signalling 
Technology  
MA, USA 1:50 
60min  
RT1 
EnVision+ 
Rabbit 
Intracellular  
signal 
mediator AKT 
10min750W 
15 min 350W 
Citrate pH 6 #4685  
Cell 
Signalling  1:50 
Overnight 
4grC 
EnVision 
FLEX+ 
Rabbit 
Intracellular  
signal 
mediator pAKT 
10min750W 
30 min 350W 
TrisEDTA pH 9 
Ser437 
#971 
Cell 
Signalling 1:10 
Overnight  
4grC 
EnVision+ 
Rabbit 
Steroid  
receptor ER 
10min750W 
15 min 350W 
TrisEDTA pH 9 
ER50  
M7047 
Dako, 
Copenhagen 
Denmark 1:50 
30 min 
RT 
EnVision+ 
Mouse 
Steroid  
receptor PR 
10min750W 
15 min 350W 
TrisEDTA pH 9 
PR 636  
M3569 Dako 1:150 
30min 
RT 
EnVision+ 
Mouse 
Cell cycle  
regulator TP53 
10 min 750W 
15 min 350W 
TrisEDTA pH 9 
TP53  
M7001 Dako 1:1000 
60min  
RT 
EnVision+ 
Mouse 
1RT : Room temperature 
4.3 Evaluation of staining 
Slides were evaluated blinded for patient characteristics and outcome by two of the 
authors (J.T and H.B.S) using a standard light microscope. A semiquantitative and 
subjective grading system described in several earlier publications138,143,175, 
calculating a staining index (range 0-9) consisting of the product of staining intensity 
(0-3) and area of tumour with positive staining (0= no staining, 1= <10%, 2 = 10-50% 
and 3 >50%). ER, PR and TP53 staining were mainly expressed in nuclei, Stathmin 
and AKT in the cytoplasm, while Phospho-AKT was expressed both in nuclei and 
cytoplasm. In line with earlier studies138, lower quartile was defined as the cut-off for 
loss of ER and PR, corresponding to staining index <3 and 0 respectively (Paper IV). 
For TP53 (index >4, Paper IV) and Stathmin, AKT and Phospho-AKT (all indexes 
>6, Paper I) upper quartile was used as cut-off, similar to earlier publications.96, 143 In 
Paper II, the overall staining intensity in hysterectomy specimens were stronger, 
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corresponding to staining index = 9 for the upper quartile, while for curettage the cut-
off remained as >6. The staining intensity was not related to differences in fixation 
time neither for curettage nor hysterectomy specimens recorded for 126 random 
patients (p = 0.43 and p = 0.40 respectively, Pearson’s Chi-square test).  
Inter-observer reproducibility have been evaluated for ER, PR, TP53 (curettage) and 
Stathmin (curettage and hysterectomy specimens) by rescoring random slides blinded 
for previous scoring for 97, 104, 76, 168 and 88 cases yielding Kappa-values of 0.91, 
0.88, 0.86, 0.72 and 0.86 respectively.     
4.4 mRNA analysis - gene signature 
Biopsies from representative part of primary tumours sampled at primary surgery 
from the hysterectomy specimens were snap-frozen and subsequent ground to powder 
in a mortar under liquid nitrogen. Tumour content was evaluated in adjacent 
haematoxylin stained frozen sections and confirmed to have tumour purity of more 
than 50% and for the majority > 80%. Total RNA was extracted using the RNeasy kit 
(Qiagen, Hilden, Germany) according to manufacturer protocol. Quality and yield of 
total RNA was assessed by agarose electrophoresis, Agilent Bioanalyser 2100 and 
spectrophotometry. Cy-3 labelled cRNA was hybridized on Agilent G4112F Whole 
Human Genome (4x44k). Oligo Microarrays with SurePrint Technology 
(www.agilent.com) and hybridization data were extracted and formatted as 
published.176
A multigene signature representing activation of the PI3K pathway was obtained from 
previously published expression data comparing cell lines transfected with PIK3CA 
(p119α) with GFP controls. The PI3Kinase signature included 495 genes that varied 
significantly in expression (Bonferroni-corrected 2-sided t-test P-value of 0.05) 
between control cells and the cells with PI3K pathway activity.96  Expression data of 
these genes were in our data set normalised for each gene to a common mean and 
scaled to the same standard deviation. The PI3Kinase activation score was calculated, 
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subtracting the sum of expression values of genes significantly down-regulated in 
cells with PIK3CA activation (relative to cells with GFP controls) from the sum of 
expression values of genes up-regulated in these cells.96
4.5  Plasma analyses 
As part of the MoMaTEC trial blood samples have been collected before primary 
treatment of participating women. EDTA-blood vials were centrifuged 2000 rounds 
per minute for 10 minutes and plasma stored at -80ο until analysed. Patients where 
blood samples were available (n=466) differed somewhat from the unsampled women 
by having higher parity, BMI, histological differentiation, and more radical surgical 
treatment including lymph node sampling as shown in table 14.
Table 14 Comparison of distribution of patient and histopathologic characteristics 
from 564 Haukeland patients with blood analysed for GDF-15(n=466) or no analyses 
performed (n=98).
Characteristics GDF-15 not 
performed      
n (%) 
GDF-15 
performed 
n (%) 
P-value 
Age  >66years 55 (56) 216 (46) 0.08 
Para >11 72(74) 397 (85) <0.01 
Postmenopausal 89 (91) 408 (88) 0.36 
BMI >25.0(kg/m2)2 43 (51) 258 (65) 0.02 
Myometrial infiltration >50%3 23 (29) 169 (37) 0.17 
FIGO 2009 stage III/IV 24 (25) 75 (16) 0.05 
Curettage histology non-endometrioid4 23 (25) 79 (17) 0.10 
Curettage differentiation grade 34 33 (35) 112 (24) 0.03 
Hysterectomy histology non-endometrioid  26 (27) 87 (19) 0.08 
Hysterectomy differentiation grade 35 43 (44) 153 (33) 0.04 
Primary surgery curettage or debulking 20 (20) 11 (2) <0.001 
Lymph node sampling not performed 38 (39) 92 (20) <0.001 
Metastatic lymph nodes 4 (7) 45 (12) 0.22 
Missing data 12 for parity, 283 for BMI, 329 for myometrial infiltration, 410 for 
curettage histology and differentiation, 55 for hysterectomy differentiation 
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GDF-15 analyses were performed by an immunoradiometric sandwich assay using a 
polyclonal, affinity chromatography-purified goat anti-human GDF-15 IgG antibody 
(R&D Systems, Minneapolis, MN). Analyses were performed in duplicate, blinded 
for clinicopathological data, in the laboratory where the assay have been developed at 
the Department of Cardiology and Angiology, Hannover Medical School, Hannover, 
Germany. This assay has a detection limit of 20 ng/l, an intra-assay imprecision of <
10.6% and an inter-assay imprecision of < 12.2%. The method is further described by 
Kempf et al.177 All endometrial cancer samples were analysed in same run, reducing 
inter-assay variation. 
4.6 Statistical methods  
Statistical analyses have been performed by the statistical program PASW 18 
(Predictive analytics SoftWare Statistics version 18.0, IBM, New York, USA). 
Categorical associations were assessed by Pearson’s chi-square test, substituted by 
Fischer’s exact test if estimated expected counts less than 5. Linear-categorical 
comparisons have been performed by Mann-Whitney test. Receiver operating 
characteristics ROC-curves were constructed by plot of 1-specificity (false positive 
rate) against sensitivity (true positive) test values. Differences in disease-specific and 
overall survival, censoring patients alive at last date of follow-up, were estimated by 
log-rank (Mantel-Cox) test, while univariate analyses of time to death were performed 
by the Kaplan-Meier method. Variables with significant impact in univariate survival 
analyses were further evaluated by log-minus-log plot to decide if these could be 
incorporated in the Cox’ proportional hazard regression model, in addition several 
categories were tested for interaction. Unadjusted and adjusted multivariate hazard 
ratios (HR) were thus estimated. Binary logistic regression was used to evaluate odds 
ratios (OR). All statistical tests were two-sided and considered statistical significant if 
p<0.05 with the exceptions of testing the one-sided hypothesis that overexpression of 
immunomarkers correlated with measures of PI3Kinase-score (Paper I) and that high 
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GDF-15 in the small pilot Ullevaal cohort correlated with metastatic disease and poor 
survival (Paper III). Cut-off values for the different categorizations were based on 
tertiles or quartiles, considering the frequency distribution for each marker, size of 
subgroups and number of events, merging groups with similar survival.  
4.7 Approvals  
This study has been approved by the Norwegian Data Inspectorate (961478-2), the 
Norwegian Social Science Data Services (15501) and the local Institutional Review 
Board (REKIII nr. 052.01). The MoMaTEC trial have been registered at the Clinical 
Trials Website (NCT00598845).178 The funding source has had no influence neither 
regarding evaluation of results nor in writing of the papers or thesis. 
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5.   Main results 
Paper I 
In this study we found the immunohistochemical Stathmin expression in tumour from 
hysterectomy specimens to be strongly correlated with aggressive clinicopathological 
characteristics such as high histological grade, deep myometrial infiltration, vascular 
invasion, high mitotic rate, loss of estrogen and progesterone receptors and poor 
recurrence-free as well as disease-specific survival. Analysing endometrioid tumours 
separately, those over-expressing Stathmin demonstrated a similar significant poor 
patient prognosis. Stathmin overexpression in curettage specimens correlated 
significantly with high histological grade, high mitotic rate, aneuploidy and estrogen 
receptors loss, but showed weaker correlation with survival. Neither for AKT nor 
phospho-AKT was there any clear correlation with clinicopathological tumour 
features nor survival. High PI3Kinase activation score was significantly associated 
with overexpression of Stathmin but not with phospho-AKT or AKT expression. 
Paper II  
Immunohistochemical overexpression of Stathmin was detected in 37% of the 
curettage and in 18% of the hysterectomy specimens investigated. Stathmin 
overexpression in curettage as well as hysterectomy specimens were highly correlated 
and significantly associated with non-endometrioid histology, high grade and 
aneuploidy. In addition high Stathmin staining in curettage specimens also correlated 
with lymph node metastasis and high FIGO stage. Stathmin analysis in curettage 
samples was an independent predictor of lymph node metastases also when adjusting 
for the available preoperative histological subtype and grade. High Stathmin 
expression both in curettage and hysterectomy specimens was associated with poor 
disease-specific survival. Endometrioid tumours with overexpression of Stathmin in 
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curettage specimens correlated significantly with poor prognosis and a similar 
tendency was seen when analysing the hysterectomy specimens. High Stathmin 
expression, in curettage as well as from hysterectomy specimens, was a significant 
predictor of poor survival both in univariate and in multivariate Cox analysis, 
adjusting for age, FIGO stage, histological subtype and grade. 
Paper III
Median plasma GDF-15 concentration from the endometrial cancer patients was, 
similar to the ovarian cancer group, significantly higher than levels measured in 
healthy pre- and premenopausal women or in women with benign or borderline 
ovarian tumours. In the large validation cohort of endometrial carcinomas, high 
plasma GDF-15 was significantly associated with FIGO stage III/IV disease, non-
endometrioid histology, high grade, older age, postmenopausal status and lymph node 
metastases. Even when adjusting for age and preoperative histological risk 
classification based on preoperative biopsy, plasma GDF-15 independently predicted 
increased risk of lymph node metastasis. High GDF-15 was also an independent 
predictor of poor disease-specific and recurrence-free survival. 
Paper IV
Focusing on the well-established immunohistochemical prognostic biomarkers 
estrogen receptor, progesterone receptor and the tumour suppressor TP53 in this 
paper, we validated their prognostic value when tested in preoperative curettage 
specimen in a large prospective multicenter setting. 18% of tumours were double 
negative for estrogen- and progesterone receptors (ER-/ PR-) while 23% over 
expressed TP53. Pathologic expression of each marker correlated significantly with 
high age at diagnosis, high FIGO stage, non-endometrioid histology, high grade, 
metastatic nodes and poor prognosis. Double negative ER-PR also correlated with 
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deep myometrial infiltration. 72% of patients were subjected to nodal sampling, of 
which 12% had metastatic nodes. Double negative receptor status independently 
predicted lymph node metastasis adjusted for preoperative curettage histology. A 
combination of high-risk preoperative histology and double negative hormone 
receptor status was the strongest predictor of metastatic nodes. ER-PR negative status 
independently predicted poor survival adjusted for age, FIGO stage, histological type, 
grade and myometrial infiltration. Within the low-risk endometrioid grade 1-2 
tumours, ER-/PR- status independently predicted recurrence. For patients not 
subjected to lymph node sampling, double negative ER-PR status predicted poor 
survival even when adjusted for age, FIGO stage, myometrial infiltration histological 
type and grade. Even for the lymph node negative endometrioid tumours, ER-PR 
negative status influenced survival independent of tumour grade. 
Paper V
In line with the increased incidence in Norway, the number of patients treated from 
Hordaland County increased from 286 (1981-90) through 307 (1991-2000) to 484 
(2001-2010). The main changes in treatment these three decades were a significant 
increase in routine pelvic lymphadenectomy performed from 0% through 9% to 77%, 
adjuvant radiotherapy declined from 75% through 48% to 12% while adjuvant 
chemotherapy increased from 0% through 3% to 9%. During this period body mass 
index increased, the proportion of nulliparous women decreased and disease stage at 
diagnose became significantly less advanced. Disease-specific survival as well as 
overall survival increased significantly during these 30 years. Adjusting for age, 
parity, BMI, FIGO stage, myometrial invasion and histological subtype and grade; 
treatment period had independent prognostic significance in multivariate analysis, but 
was no longer significant when adjusting for type of surgical treatment. 
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6. Discussion  
Endometrial cancer is available for histopathological investigation by pipelle biopsy 
or dilatation and curettage. The information regarding histologic subtype and 
differentiation grade is used for risk assessment and planning of surgery including 
lymph node sampling. Still, the histopathological information based on curettage 
tissue is discordant with the final diagnosis based on investigation of the hysterectomy 
specimen regarding subtype in 67 to 83%179, 180 and grade in 36 to 63%.41, 44 In many 
cases, curettage tissue is insufficient for reliable determination of type and grade. The 
prediction of prognosis by preoperative histologic information has rarely been 
addressed in the present literature. Thus, reliable biomarkers applied in preoperative 
curettage or blood samples will potentially be helpful tools to differentiate between 
low- and high-risk patients for lymph node metastasis and poor survival. 
6.1  Discussion of materials
6.1.1 The patient cohorts  
The Hordaland cohort 
The Hordaland cohorts (Paper I and V); the first decade 1981-90 has been verified to 
contain 94% of patients with endometrial cancer from Hordaland County (Hordaland 
comprising 10% of the total Norwegian population) by crosschecking data from the 
compulsory Norwegian Cancer Registry with the patients retrieved from the hospital 
records. The identification and follow-up of patients from the two latter decades has 
been performed by similarly checking hospital files and the Cancer Registry for 
follow-up data. The age distribution, incidence and stage distribution of  endometrial 
carcinoma in Hordaland is paralleled in Norway in general2, thus our cohort is 
considered representative for Norwegian endometrial cancer patients during the time 
span investigated. 
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The MoMaTEC cohort (Paper II, III and IV)  
Haukeland, being a tertiary cancer centre, treat patients with significantly more 
aggressive subtypes and higher FIGO stage than several other Norwegian hospitals. 
Similarly, the Swedish and Belgian cancer centres recruited patients with similar 
characteristics as those from Haukeland, thus the whole MoMaTEC cohort is to some 
extent enriched for aggressive tumours. Still, the percentage of positive lymph nodes 
is 12% and within the range reported from other studies: 13.3% from the Mayo 
clinic181, 10.8% in the ASTEC trial79 and 13.4% in the Italian study by Panici and co-
workers.78 The selection criteria for sampling were uniform in seven Norwegian 
centres: sampling in principle all patients, but omitting those with severe co-
morbidities or if hyperplasia was the preoperative diagnosis. Loeven and Ullevål 
omitted sampling also in small Grade 1-2 tumours (< 2cm) with <50% myometrial 
infiltration. Sahlgrenska sampled only intermedium risk patients defined as having 
only one of the following risk factors; >50% myometrial invasion, TP53 positivity, 
aneuploidy or Grade 3 differentiation. This is reflected in the lower percentage of 
patients sampled amongst the non-Norwegian centres (see table 9). Mean number of 
nodes sampled was also significantly different between these hospital groups; 25 for 
the non-Norwegian compared to 15 for the Norwegian centres, p<0.001, still the 
frequency of metastatic nodes were not significantly higher 16.8% versus 11.5%, 
p=0.095. The overall mean and median numbers of nodes sampled (16 and 14, 
respectively) is similar to the ASTEC trial (median 12) but lower than the Panici trial 
(median 26 pelvic, 30 total).78, 79
Our study protocol included and recorded pelvic lymph node sampling. We have no 
systematic information whether additional para-aortal sampling was performed, thus 
the studies evaluating biomarkers as predictors of metastatic lymph nodes (Paper II, 
III and IV) can not necessarily be applicable in relation to para-aortal metastasis. 
76
For the Norwegian centres, the routines for administration of adjuvant treatments 
were consistent, while the non-Norwegian centres provided significantly more 
radiation therapy. When evaluating survival effects of adjuvant treatment in our 
studies, adjuvant therapy showed no independent impact. This appears to be in line 
with several studies not finding any survival benefit from radiation therapy for early-
stage endometrial cancer.182
We have information about the proportion of patients included in the MoMaTEC trial 
for 8 of 10 participating centres recruiting 1149 of the 1192 included patients. In total 
1499 women have been treated for endometrial cancer at these centres, thus 77% of 
all potentially eligible patients were included and clinical and follow-up information 
provided, ranging from 25 to 38% from the small hospitals (Tønsberg, Haugesund 
and Førde) while the large centres ranged from 40 to 99% (Ullevål, Trondheim, 
Sahlgrenska, Leuven and Haukeland).  
In sum, the distribution of clinical characteristics for the patient series from the 
different including hospitals is relatively homogenous, supporting that results from 
our studies most likely will be valid be for endometrial cancers from Norway, 
Scandinavia and Northern Europe dominated by a Caucasian population.
Retrospective versus prospective series 
The two first cohorts from the Hordaland County were retrospectively collected, 
while the last cohort as part of the MoMaTEC trial was prospectively recruited. Thus, 
results from exploratory investigations of biomarkers from the early series (Paper I) 
and earlier studies138, 143 could now be validated in the larger MoMaTEC multicentre 
trial (Paper II and IV). 
Since histologic subtyping was not routinely performed in the early periods studied, 
histopathological revision was performed for the Hordaland 1981-1990 series, while 
the diagnosis from the routine pathology reports were considered valid and applied 
for the prospective validation series, also aiming to investigate if biomarkers could 
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contribute additional information to the diagnostic tools applied in a standard 
everyday basis for clinical decision making. 
6.1.2 Tissues/samples available 
Curettage versus hysterectomy specimens 
Hysterectomy specimens have only been collected from Haukeland (Paper I and II), 
while curettage/preoperative biopsy specimens have been collected from all centres. 
Using curettage/biopsy specimen rather than hysterectomy specimen for analyses of 
biomarkers has the potential advantage that they may be used for preoperative risk 
analyses and aid in planning and stratification of treatment. The disadvantage is that 
compared to final hysterectomy specimens, biopsy material is often sparse, 
representing more superficial parts of the tumours. Zonal differences that may be of 
importance, such as the invading and more deeply invasive front of the tumour, may 
be less accessible for investigation using curettage tissue.  
Freshly frozen tissue 
For Paper I, freshly frozen tissues from 76 patients have been used for mRNA 
expression analyses. These patients did not differ significantly from the patients from 
the 1981-90 Hordaland cohort, as seen in table 7. However, one should be aware of a 
potential enrichment for high risk cases in studies aiming for >80% of tumour purity 
in the inclusion criteria. Analysing a larger set of 273 freshly frozen tumour biopsies 
from the MoMaTEC series, demonstrates a significantly higher proportion of non-
endometrioid, high grade tumours in samples with >80% tumour purity.183
Blood samples 
For the preoperatively collected blood samples (Paper II), we see a different potential 
selection bias; significantly more of those without blood samples available for 
investigations were nulliparous, with normal body weight with high grade tumours 
not radically treated by surgery, while FIGO stage was not significantly different. 
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Thus, the study population appears to some extent to be enriched for patients with 
favourable risk factors. 
TMA specimens  
For curettage specimens, we find that tissues from patients with non-endometrioid 
and high grade lesions were significantly less often representatively mounted in the 
TMA blocs for immunohistochemical evaluation (see table12). There was no 
correlation between parity or type of surgical treatment and whether tissues were 
available for analysis in TMAs or not. A reason for this finding may be that non-
endometrioid tumours are arising in an atrophic and more scant endometrium184, 
yielding more scarce material for biopsies than the endometrioid tumours from an 
abundant hypertrophic endometrium. Similarly, high grade tumours may be more 
prone to necrosis also leaving less viable tissue for TMA processing. The overall 
availability of 841 specimens analysed is still relatively high, representing 75% of all 
patients, thus even the rarer non-endometrioid subtypes and high grade endometrial 
lesions are present in 29% and 13% of the cases respectively, permitting analyses to 
be valid also for these categories. Former biomarker studies of curettage specimens 
regarding lymph node metastasis or survival have had non-endometrioid subtypes 
present in 8.9% of 236 tumours analysed143, 14.9% of 134164, 18.4% of 136162, 20% 
of 7665 and 27% of 125.163 Our relatively high proportion of non-endometrioid 
tumours may be related to the inclusion of carcinosarcomas representing 4% of our 
study population, often being excluded in earlier studies.143
6.2  Discussion of methods
6.2.1 Immunohistochemistry applied in curettage tissue 
We have used antibodies that from earlier studies in our centre have shown good 
correlation of expression between curettage and hysterectomy specimens: TP53 
(p<0.0001)143, ER and PR (p<0.001).138 P16, although prognostically relevant in 
earlier analysis, did not show a similar strong statistical significant correlation 
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between expression in curettage and hysterectomy specimens (p=0.06)143, one reason 
for not investigating this marker in the present studies. 
Due to our recent data suggesting the importance of PI3Kinase activation in 
aggressive endometrial cancers96, we also wanted to investigate new, candidate 
biomarkers reflecting PI3Kinase activation in hysterectomy specimens from a 
retrospective cohort (AKT, phospho-AKT and Stathmin in Paper I). We found a 
correlation between Stathmin overexpression, PI3Kinase activation and poor 
prognosis, but none of the other investigated markers were significantly correlated 
with PI3Kinase activation or prognosis. Stathmin was further investigated in curettage 
specimens and found to be a marker for poor prognosis. Also, further investigations in 
the prospective cohort of hysterectomy as well as curettage specimens, validated the 
association between Stathmin expression and phenotype (Paper II). High Stathmin 
expression was significantly correlated with poor prognosis based on investigations of 
curettage and hysterectomy specimens, both p-values <0.001, for the retrospective 
series, and p=0.002 in the prospective series. 
Fixation time is often different for hysterectomy versus curettage specimen, 
potentially influencing performance of immunohistochemical investigations. We have 
evaluated this for Stathmin; 126 randomly selected corresponding curettage - 
hysterectomy sample pairs. The fixation time was significantly shorter, median 1 day 
for curettage as compared to 6 days for hysterectomy specimen, but there were no 
correlation with fixation time and immunohistochemical expression of Stathmin for 
neither of the specimens. This marginal effect of fixation time on staining intensity is 
in line with other immunohistochemical staining studies.185
6.2.2 Tissue MicroArray (TMA) 
We have used TMAs for all immunohistochemical investigations in our studies 
(Paper I, II and IV). TMA is a good method of high output analysis with the benefit 
of investigating large numbers of samples at the same time. Testing all or most of a 
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series investigated for the same antibody in one run reduces potential variability in the 
staining technique. Selecting representative tissue for TMA preparation aiming for the 
least differentiated and probably most aggressive component of the tumour will 
potentially not reflect all of the biologic diversity in the tumour.  To increase 186
representativeness and reduce case drop-outs, we included three 0.6 mm cores from 
each tumour sample, in line with most recommendations.174  
Storing time of the formalin fixed paraffin embedded tissue blocks has also been 
shown to reduce staining intensity for several antibodies.185 Even for our prospective 
series (initiated 2001), the tissues have been stored variable amount of time before 
TMA was processed, starting in 2008. Testing for the influence of storing time using 
3-year intervals showed no cumulative trend change in staining scores for any of the 
four investigated biomarkers ER, PR, TP53 or Stathmin (p>0.05 for all). 
Although TMA is very useful in an investigational setting, markers explored using 
this technique will have to be validated in full sections before applied in a clinical 
setting. 
6.2.3 Immunohistochemistry 
Morphological characteristics of tissues are the cornerstone in histopathologic 
diagnostics, but immunohistochemistry (IHC) may aid in the detection of biologically 
relevant functional changes in tumours. Immunohistochemical staining procedures 
involves many steps; deparaffinization, epitope demasking through antigen retrieval, 
antibody dilution, incubation length and temperature as well as final antibody 
detection and counterstaining, each with potential pitfalls. We have used stringent 
protocols developed in the research laboratory over several years, and for TP53, ER 
and PR they have been firmly established.138, 143 For Stathmin, AKT and phospho-
AKT test stainings were performed according to manufacturer’s suggestions 
exploring different buffers during microwave antigen retrieval as well as different 
dilutions of antibody, temperature and length of incubation. Stainings were evaluated 
against tissues known to express and not express the relevant antigen, as well as 
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substituting the antibody with diluent only, as negative control. The final protocols are 
summarized in table 13. 
6.2.4 Cut-points for staining indices
To evaluate the stainings, a semiquantitative score incorporating both staining 
intensity and area of staining was used. This scoring system was developed in our 
research laboratory175, and has been used for several antibodies and in several tumour 
types.187, 188 Our scorings were performed blinded for the patients’ clinical and 
outcome data. When evaluating cut points, the frequency distribution for each marker 
was considered in relation to the size of subgroups and number of events in each 
category. Groups with similar survival were merged. In line with former studies, 
lower quartile for ER and PR and upper quartile of TP53 expression were considered 
pathologic.138, 143 For ER, the lower quartile included staining index 0-3, while for PR, 
all specimens in lower quartile had no nuclear staining at all (Index=0). When 
determining cut-points for IHC stainings it is generally recognized that this has to be 
evaluated at each centre according to actual antibody used and population studied. 
This appears to be in line with what is applied for breast cancer, where estrogen 
receptor testing has been performed for several years in a routine clinical setting. The 
definition of receptor negative tumours is also not restricted to only staining index = 
0. There are large studies using 10% of cells staining positive as upper limit for 
receptor negativity189, while the joined guidelines of the American Society of Clinical 
Oncology and the College of American Pathologists now recommends a limit of 1% 
tissue with nuclear staining.190 The latter limit increasing the proportion of ER 
positive tumours is chosen in order not to miss patients with ER positivity who could 
possibly benefit from the relatively non-toxic tamoxifen treatment. 
For Stathmin, the upper quartile corresponded to index >6 in the curettage samples 
and index =9 in the hysterectomy specimens in the largest prospective series, while 
for the retrospective series the upper quartile correspond to index >6 as cut-off value 
for both specimen types. The explanation for this is not clear. The prospective series 
were stained during the same run at the same day for curettage and hysterectomy 
TMA slides, still the hysterectomy specimens appeared to generally have significantly 
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higher staining indices. As already mentioned, fixation time did not significantly 
influence staining indices. Since staining is higher in non-endometrioid and high 
grade tumours, differences in the proportion of these for the two TMA series could be 
another factor. However, these were not overtly different: for the curettage specimens 
the proportion of non-endometrioid cases and high grade endometrioid tumours were 
15.7 and 13.3% while for the hysterectomy specimens these were 17.8 and 13.9% 
respectively. Still, the TMAs from hysterectomy specimens may contain a selection 
from more undifferentiated tumour parts than the curettings. These differences in cut-
offs illustrate that the process from the exploration and investigation of a new 
antibody until an optimal staining procedure and cut-off limit for use in clinical 
practice is developed, is cumbersome and will need to involve many validation steps. 
This can be illustrated by the timeframe from the first investigations of the HER2/neu 
oncogene in 1984 until the American Society of Clinical Oncology and the College of 
American Pathologists published standardised joint guidelines for HER-2 testing in 
breast cancer in 2007.160
6.2.5 Plasma analyses 
Analyses from the endometrial cancer patients (both the Oslo and the Haukeland 
cohort) were run in duplicate and all samples in same run. GDF-15 has been analysed 
from preoperative plasma samples collected from 2001 through 2009. Potentially 
different preanalytic storage time could influence the measurement, however, 
correlating year of diagnosis with proportion of high GDF-15 levels showed no 
cumulative trend change (p>0.05).  
6.2.6 mRNA gene signature analysis 
Microarray analysis, yielding signature scores for different signalling pathways, is a 
powerful tool in cancer research. It may identify potential new targets for treatment in 
aggressive tumours, defined by specific gene expression patterns that potentially may 
benefit from specific targeted therapies. Such microarray studies involve complex 
bioinformatics and integrated analyses, which had been performed prior to the present 
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study.96 In the present thesis we have applied these data regarding activation of one 
such gene signature, tested in 76 freshly frozen primary tumours in relation to the 
protein expression of Stathmin, AKT and phospho-AKT to investigate which protein 
might best reflect the signature (Paper I). 
6.3  Discussion of results  
6.3.1 Improved prediction of lymph node metastasis
Lymph node metastasis is a highly significant marker for poor survival in endometrial 
cancer. Therefore it has been incorporated in the surgical staging as a separate entity 
in the FIGO classification.64 In a recent publication comparing FIGO 88 versus FIGO 
09 classification191, patients with lymph node metastasis FIGO 88 stage IIIC had 5-
year disease specific survival of 59% and according to the FIGO 09 criteria 60% if 
only pelvic nodes were involved (FIGO IIIC1) and 53% if aortic nodes were positive 
(FIGO IIIC2). Still, systematic pelvic lymph node sampling has not proved to increase 
survival in randomised trials.78, 79 Sampling increases operation time and surgically 
related morbidity, such as postoperative ileus and deep-vein thrombosis with a RR 
1.23 (95% CI 1.04-1.45) as well as the risk of lymph cysts or lymph oedema in the 
legs with RR 8.39 (95% CI 4.06-17.33).80 When only 12% of sampled patients have 
positive nodes as in our study, the sampling of the vast majority (88%) may contribute 
to increased morbidity with no benefit for these patients.  
Depth of myometrial infiltration, histological subtype as well as histological grade has 
all been found as independent predictors of poor prognosis.49, 70, 153, 155  These factors 
can be combined in different ways for risk stratification. The Mayo clinic defines 
patients as low-risk if endometrioid Grade 1-2 histology and <50% of the thickness of 
the myometrium is invaded by tumour cells.51 This is in line with risk stratification 
presently used in Norway40 as well as by the ASTEC-group.182 A retrospective cohort 
study by Convery and co-workers confirmed that for this low-risk group, the 
prevalence of metastatic nodes was very low, 2% of those with sampling performed, 
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and neither recurrence- nor progression-free survival were significantly influenced by 
lymphadenectomy.192  
The results from the studies of Mariani and Convery are based on intraoperative 
frozen section assessment of histopathology including depth of myometrial 
infiltration. Many centres do not have such pathology service as readily available, and 
thus will have to rely more on gross inspection of infiltration depth and preoperative 
assessment of histopathology. Applying preoperative curettage histology, the low-risk 
group defined as endometrioid histology grade 1-2, identified a patient subset with 
8% risk of lymph node metastasis in our MoMaTEC population. Taking into account 
the information regarding ER-PR status does not alter this 8% risk for lymph node 
metastasis, even when only ER-PR positive endometrioid grade 1-2 tumours were 
defined as a low-risk group. However, for the high-risk group, preoperative diagnosis 
of non-endometrioid or endometrioid grade 3 histology, ER-PR negative tumours had 
a significantly higher frequency of metastatic lymph nodes: 29% as compared to 18% 
for ER-PR positive high risk histology patients. In comparison, high Stathmin 
expression in combination with high-risk preoperative curettage had a 26% risk of 
metastatic lymph nodes.  
We have not found TP53 to be of independent value in predicting lymph node 
metastasis. This is in contrast to the study from Mariani and colleagues where TP53 
was an independent predictor when adjusted for histological subtype or grade as well 
as the apoptosis marker BCL-2.65. Their study is smaller, using a case-control design 
of 82 patients as compared to our 605 patients with available data from 
immunohistochemical staining and lymph node sampling. Contrasting our study, they 
did not include hormone receptor status in their investigation, which also may have 
contributed to the difference. We found ER-PR to be a stronger predictor than TP53, 
thus TP53 was not of independent predictive significance for lymph node metastasis. 
The same applies to our series if we simultaneously add Stathmin and ER-PR status to 
the logistic regression; Stathmin looses its independent predictive value for lymph 
node metastasis contrasting double negative ER-PR with the significant OR of 2.32 
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95% (CI 1.28-4.21) adjusting for curettage risk groups. Thus, based on our results, 
aiming to improve prediction of metastatic nodes in a routine setting, we would 
recommend testing for ER-PR in preoperative specimens and opting for lymph node 
sampling if preoperative histology is non-endometrioid or endometrioid grade 3 or 
double negative for hormone receptor status.
Hormone receptor status has been routinely applied in the breast cancer diagnostics 
for several years. Thus, pathology laboratories have thorough knowledge and 
experience with these stainings shown to be robust and have high reproducibility. 
These have now been validated in a prospective multicentre setting regarding 
endometrial carcinoma (Paper IV). 
6.3.2 Immunomarkers predicting survival 
Several immunomarkers tested in hysterectomy specimens have been reported to 
predict survival. Those most consistently reported with independently prognostic 
value are ER, PR and TP53.138, 161, 163 These markers have shown to be of importance 
in many other cancer types as well, notably breast and ovarian cancers.190, 193, 194
Based on the potential targetable nature of the PI3Kinase pathway often elevated in 
aggressive endometrial cancers, we explored a panel of immunohistochemical 
markers for their possible applicability to detect PI3Kinase signalling pathway 
activation. We have investigated AKT, phospho-AKT (pAKT) and Stathmin. The role 
of phospho-AKT staining as a prognostic marker has been explored in other cancer 
types, such as ovarian195, 196, breast197, 198 and cervical cancer199, with conflicting 
results: only two of these studies, those of Guo and co-workers and Wu and 
collaborators, showed an independent value in relation to survival.  
Previous studies of endometrial cancers have found the immunohistochemical 
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expression of phospho-AKT to vary considerably, from 40%200 to 100%.201 Likewise, 
the relation to clinico-pathologic phenotype is inconsistent, as one study reported a 
correlation between high phospho-AKT and deep myometrial infiltration,202 while 
two others did not find any association with clinical or pathological factors.203, 204 In 
our study (Paper I), we found no correlation of phospho-AKT neither in relation to 
clinico-pathological characteristics nor survival. None of those studies that have 
investigated phospho-AKT in endometrial cancer have demonstrated this as an 
independent prognostic factor, in line with our findings.     
The fact that we find that phospho-AKT staining is not related to activation of the 
PI3Kinase signalling level at the mRNA level (Paper I), supports that phospho-AKT 
may be a reliable pathway marker under highly controlled situations, as found in cell 
culture studies, but that the available reagents do not work well in routinely collected 
clinical specimens.118
For AKT immunohistochemical staining, no correlations with clinico-pathological 
factors and survival have been reported from several studies investigating breast-, 
gastric- and bronchial cancers.205-207 Our study of endometrial carcinomas adds to this 
general impression that AKT is not valuable as a cancer prognosticator. Also, we find 
that AKT staining is not related to activation of the PI3Kinase signalling level at the 
mRNA level (Paper I).
Stathmin has been found to correlate with aggressive clinico-pathological features and 
poor prognosis in several cancers115 as breast-118, 208, ovarian-209 and cervical 
cancers.210 One study supported Stathmin as a surrogate marker of PI3Kinase pathway 
activation, and of independent prognostic value.96 In Paper I we found high 
expression of Stathmin in hysterectomy specimens to correlate with high PI3Kinase 
mRNA activation score as well as being an independent predictor of poor survival. In 
Paper II we validated high Stathmin expression in tumour samples from 
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hysterectomy specimens to be an independent prognosticator with HR of 1.68 (95% 
CI 1.13-3.35) adjusted for age, FIGO stage, histologic type and grade.  Another study 
exploring biomarkers in paired primary tumour versus biopsy from recurrent lesions, 
demonstrated Stathmin expression in the primary tumour to be significantly changed 
(defined as > 2 step change in staining index) in the recurrent lesion in 38% of cases, 
although expression status in the metastatic lesion in itself, was not correlated with 
survival.211 Currently, we have not found any other studies published exploring 
Stathmin in endometrial cancers.  
6.3.3 Immunohistochemical analyses in curettage specimen as prognostic 
markers 
Markers in curettage specimens consistently reported to add prognostic information 
are immunohistochemical stainings for estrogen receptor (ER), progesterone receptor 
(PR) and TP53.138, 143, 162, 163, 201 These are predominantly retrospective studies with 
fewer patients included than in the present studies. The study of Oreskovic and 
colleagues162 included 136 patients and found curettage TP53 of independent 
prognostic value whereas ER and PR were not. Engelsen and co-workers found TP53 
and hormone receptors to have independent significance in their study of 236 patients; 
TP53 with a HR of 2.8 (95%CI 1.5-5.6) while ER or PR each had a HR of 2.6 
(95%CI 1.3-5.4) when investigated simultaneously in multivariate analysis.138 The 
study by Steinbakk and co-workers201 found TP53 combined with p21 and Survivin to 
be independent prognosticators of survival in their cohort comprised by FIGO stage I-
II tumours; however ER or PR was not investigated. 
In our larger prospective MoMaTEC trial (Paper IV) we find double negative ER-PR 
to have independent significant prognostic value and an HR 1.99 (95% CI 1.12-3.53) 
for disease specific death when adjusting for age, FIGO stage, myometrial infiltration, 
endometrial subtype and grade, while TP53 lost its independent prognostic 
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significance.  
In Paper II we found that high curettage expression of Stathmin adjusted for age, 
FIGO stage, histologic type and grade, independently predicted poor survival with an 
adjusted HR of 1.68 (95% CI 1.05-2.67). This HR remains unaltered even if ER-PR is 
added as a factor in this multivariate analysis. Using results from Stathmin expression 
from hysterectomy specimens still leaves Stathmin with an HR of 2.26 (95% CI 1.22-
4.21) when ER-PR is included. 
Using the risk stratification incorporating subtype, grade and myometrial infiltration 
based on final histologic evaluation of the hysterectomy specimen, being a similar 
approach as applied in the ASTEC radiation trial182, we see a significant worse 
survival in the intermediate risk group if either Stathmin expression is high (p=0.025) 
or ER-PR expression is lost (p=0.009) and similar for the high risk group with ER-PR 
loss (p=0.009) as illustrated in figure 10.   
As shown in Paper IV, loss of hormone receptor expression independently predicted 
poor prognosis in patients not subjected to lymphadenectomy, in patients with 
endometrioid tumours and negative nodes, and even within the most favourable group 
of endometrioid grad 1-2 tumours.  
Thus, both hormone receptor status as well as Stathmin expression tested in 
preoperative tissue specimens independently identifies patients with poor prognosis 
even adjusted for histological subtype and grade. This information may be available 
before initiating primary surgery and adjuvant treatment and clearly has a potential of 
tailoring treatment according to more refined risk stratification. 
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Figure 10 Disease specific survival related to risk groups and biomarker expression. A 3 
Risk groups B Stathmin expression in moderate risk group C ER-PR expression in moderate 
risk group and C ER-PR expression in high risk group. 
Low risk (blue): Grade 1-2 <50% myometrial invasion (MI) 
Moderate risk (green): Grade 1-2 > 50% MI or Grade 3 > 50% MI 
High risk (red): Grade 3 >50% myometrial invasion and all Non-endometrioid tumours 
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6.3.4 Biomarkers for treatment stratification 
Stathmin known to be participating in the regulation of microtubules, could 
potentially be related to the effects of microtubule drugs such as Taxanes. Breast 
cancer cell-line studies indicate that high Stathmin expression correlate with poor 
effect of microtubule-acting drugs and that repressing Stathmin counteracted this and 
sensitise cells to Vinblastine and Paclitaxel.114, 212 mRNA expression of Stathmin in 
pre-treatment biopsies from lung cancer patients demonstrated a significant shorter 
progression free survival in patients receiving Vinblastine.213 In ovarian cancer pre-
treatment biopsies, high mRNA expression of Stathmin likewise demonstrated worse 
progression-free survival in patients treated with Taxanes in combination with 
Platinum.209 In contrast, another study of clear cell ovarian cancers did not find such 
survival difference related to protein expression of Stathmin. One recent abstract 
(Werner et al, ESGO 2011, Milan, unpublished results) reported Stathmin expression 
as a significant predictor of response to Taxane treatment in endometrial cancer.  So 
far we have found no other papers describing this relation. Taxanes is presently one of 
the major components in chemotherapy in endometrial cancer.214 Since we find a 
relation between Stathmin expression and aggressive phenotype and poor survival, 
this would justify the investigation of Stathmin as a predictor for response to Taxanes. 
PI3Kinase inhibitors in cancer treatment are promising drugs entering clinical phase I 
and II trials97,215, also illustrated in table 3. The PI3Kinase/mTOR pathway is 
frequently upregulated in endometrial cancer.96, 139 In the study from Salvesen and 
collaborators96, Stathmin expression was found to correlate with a PI3Kinase 
activation signature. Our present study (Paper I) validates the link between activation 
of the PI3Kinase signalling pathway, Stathmin overexpression and aggressive clinico-
pathologic phenotype.  None of the recently completed trials of targeted therapies of 
the PI3Kinase- or mTOR have applied biomarkers as part of their design97, while four 
ongoing studies are now addressing this as shown in table 3. Further studies relating 
Stathmin expression and response to drugs targeting the PI3Kinase/mTOR pathway 
will be important to explore its potential value as a predictive marker.  
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Adjuvant antihormonal therapy has not demonstrated to improve survival in 
randomised trials and is thus not routinely recommended.91 Still, as these studies were 
not biomarker restricted, such therapy may have an unexplored potential for 
subgroups of patients. Hormone receptor status predicts survival and response to anti-
hormonal therapy in metastatic endometrial cancer. Gestagen therapy is often tried in 
the metastatic setting and is also an option in the primary setting for patients unfit for 
surgery due to high age and severe co-morbidity.90 Still, in contrast to breast cancer 
treatment, hormone receptor status has not yet routinely been implemented in the 
clinic to improve and individualize endometrial cancer therapy. This despite the fact 
that estrogen and progesterone receptor status has consistently been reported as strong 
prognostic markers in endometrial cancer, and again verified as an independent 
prognosticator in our large, prospective multicenter study (Paper IV). Thus, 
incorporating hormonal receptor status in a more systematic manner for clinical trials 
evaluating surgical- and systemic therapies appears to be overdue for endometrial 
cancer. 
6.3.5  The role of serological biomarkers in endometrial cancer  
At present there are no serological marker of routine use in endometrial cancer 
although the commonly used CA-125 in ovarian cancers, has been suggested also for 
endometrial carcinomas.165 GDF-15 has been investigated in other cancers, and high 
plasma levels correlated with reduced time to recurrence and reduced overall survival 
in colorectal cancer.216 In ovarian cancer high level of GDF-15 in ascites was an 
independent predictor of poor survival121, and preoperative plasma levels an 
independent predictor of poor survival.123
We have shown GDF-15 as an independent predictor of lymph node metastasis 
(Paper III). When incorporating ER-PR status in the logistic regression analysis, 
GDF-15 is still an independent predictor of lymph node metastasis with an OR of 2.64 
(95% CI 1.23-5.65, p=0.012) together with ER-PR expression with an OR 2.46 (95% 
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CI 1.02-5.93, p=0.046) Thus, GDF-15 plasma level in addition to curettage histology 
and hormone status in tumour could improve the prediction of metastatic lymph 
nodes. Also, in Cox analysis regarding disease-specific survival, GDF-15 is an 
independent predictor of poor prognosis when adjusted for age, histological type and 
grade and ER-PR status with a HR of 2.60 (95% CI 1.42-4.75, p=0.002). If our 
findings are validated in further studies, one might consider further evaluating this 
marker in relation to detection of recurrence or progression. 
6.3.6  Treatment strategies over time 
Potentially, the knowledge of negative lymph node status in properly staged 
endometrial cancer patients might lead to decreased use of adjuvant treatment. In a 
SEER study of patients treated during 1988-2006 by Sharma and colleagues, they 
found no influence from lymph node sampling in the administration of external beam 
radiation therapy for the low-risk FIGO (88) stage IA any grade or Stage IB grade 1-2 
tumours. In contrast, for higher risk groups as FIGO stage I grade 3 and stage IC any 
grade, they see a shift from external radiation towards vaginal radiation therapy if 
lymph nodes had been sampled negative.217 Still, the overall percentage of FIGO 
stage I patients receiving any radiation therapy was 25% in the lymph node sampled 
group compared to 16% in the unsampled group. This may be explained by more 
lymph node sampling performed amongst patients with high risk histology or 
suspected deep myometrial infiltration. The accompanying editorial timely points out 
that the data from the SEER study also indicate that we may be over treating patients 
as it seems like lymphadenectomy may not be altering the decision making in terms of 
using any radiation or not.81 From our MoMaTEC trial (Paper II and IV), we see a 
different pattern: only 6% of lymph node sampled FIGO (88) stage I patients received 
any radiation therapy in contrast to 18% of the unsampled patients. Similar numbers 
for the population based Hordaland cohort over three decennia, from 2001-2010 
radiotherapy was given to 3% and 9% for sampled and unsampled FIGO stage I 
patients, respectively; this is a reduction from 69% receiving radiation therapy in 
1981-1990 when no patients were sampled (Paper V). Thus, in Europe it seems like 
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lymphadenectomy has a stronger and more systematic influence on the decision 
making regarding the use of adjuvant treatment. Also, randomized studies reporting 
no survival benefit from radiotherapy may have influenced the change in treatment 
strategy seen over time.182, 218
In line with our 30-year perspective form Norway (Paper V), there has been an 
increased survival in Europe: 5-years survival has increased from 76% to 79% during 
2005-2009219; also a similar trend was found in Britain.220 In contrast, a SEER study 
has noticed an opposite trend: worse survival of their population during 1988-2001.9
The American study noticed a significant increase in non-endometrioid subtypes, and 
this was mainly found in women of Afro-American ethnicity. In the British study, 
there was no increase in the non-endometrioid subtypes, similar to the findings from 
Norway. Whether the data are derived from mandatory population based registries 
versus non-mandatory hospital based registries may also have influenced the reported 
results. 
The reduction of radiation therapy seen in Norway is in line with the conclusion of the 
randomised PORTEC-1 trial218 and ASTEC-radiation trial182, showing no survival 
benefit from adjuvant radiotherapy. Lately, there has been increased focus on 
systemic treatment for high risk endometrial carcinomas. A Cochrane review 
concluded that Platinum based therapy had an increased overall survival with HR 0.74 
(95% CI 0.64-0.89) and progression free survival of HR 0.75 (95% CI 0.64-0.89).92
The trend of adding chemotherapy for 9% of the Norwegian patients during the last 
decennium (Paper IV) and 18% of the MoMaTEC patients (Paper II and IV) thus 
seems to be in line with this recently developed knowledge. 
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7. Conclusions 
1. Stathmin immunohistochemical staining is superior to AKT and phospho-AKT 
staining in detecting PI3Kinase signalling activation and aggressive endometrial 
carcinomas with poor outcome (Paper I). 
2. Stathmin staining in primary tumours has been validated to identify endometrial 
carcinomas with aggressive clinicopathological features in a large prospective 
multicenter setting (Paper II). 
3. Immunohistochemical staining of Stathmin in preoperative biopsies (curettage) 
independently predicts lymph node metastasis and poor survival (Paper II). 
4. Plasma GDF-15 has been documented as elevated in two independent patient 
cohorts of endometrial cancer patients compared to controls. High preoperative GDF-
15 was significantly associated with aggressive phenotype and a significant and 
independent predictor for lymph node metastasis and poor survival (Paper III). 
5. Double negative hormone receptor status (ER and PR negative) in preoperative 
endometrial cancer curettage has been validated to identify patients with poor 
prognosis in a prospective multicenter setting.  ER-PR negativity independently 
predicts lymph node metastasis. (Paper IV). 
6. Reduction in adjuvant radiotherapy and increase in routine pelvic 
lymphadenectomy during the last 30 years (1981-2010) are associated with improved 
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disease-specific- and overall survival in a population-based setting of endometrial 
carcinoma patients with steadily increasing body mass index with time (Paper V).  
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8. Future perspectives 
We have validated ER, PR and Stathmin expression in preoperative specimens as 
robust markers for predicting aggressive endometrial carcinomas with increased risk 
for lymph node metastasis and poor survival. Since routine lymphadenectomy has not 
been documented to increase survival, it would be of interest to evaluate if 
incorporating ER-PR-Stathmin status can improve definition of low- and high-risk 
patients for tailored surgical therapy in a prospective randomized multicentre trial.  
Randomised trials enriched for high-risk patients based on conventional 
histopathological markers and biomarker status, can potentially improve trials 
evaluating effect of extensive lymph node surgery including para-aortal 
lymphadenectomy.  
Aneuploidy has been validated to be an independent predictor of aggressive disease 
and poor survival in endometrial cancer.132 Small-scale studies163 have found that 
preoperative assessment of tumour ploidy may predict extra-uterine disease. It would 
be of interest to further explore if assessment of DNA ploidy tested in preoperatively 
collected specimens from our large MoMaTEC cohort, can predict lymph node 
metastasis and prognosis. 
Molecularly based randomized trials of systemic antihormonal treatment may be 
important to reveal a yet unexplored potential for these drugs amongst receptor 
positive metastatic lesions, due to lack of incorporation of biomarkers in most earlier 
studies evaluating antihormonal treatment in adjuvant or recurrent settings. 
Stathmin expression was found to be an independent predictor of poor survival and a 
surrogate marker for PI3kinase signalling, and would therefore be an interesting 
candidate to test as predictive marker for response to therapy in clinical phase I/II 
trials of mTOR/ PI3Kinase inhibitors targeting the PI3Kinase pathway. 
97
Stathmin is known to be partaking in the microtubule dynamics, and high Stathmin 
has been linked to reduced effect of Taxanes in other cancers. Thus, Stathmin would 
be of particular interest to explore as a potential predictive marker for Taxane 
response in metastatic endometrial cancers as well. The role of Stathmin may be 
further explored in endometrial cancer cell lines and animal models of endometrial 
cancers. Also by evaluating Stathmin expression status in sequential biopsies from 
patients undergoing preoperative or palliative conventional and novel systemic 
treatments for locally advanced disease, may in particular offer a unique and 
alternative approach to study molecular alterations in tumour during treatment in 
relation to response, and potentially improve the clinical implementation of 
molecularly targeted therapy. 

Regarding plasma level of GDF-15, further studies are needed to explore the 
applicability of GDF-15 measurements as a marker for stratification for lymph node 
sampling or for early detection of recurrence in routine follow-up.  
Preoperative plasma GDF-15 has, in addition to endometrial cancer, been found to be 
elevated in ovarian cancer patients compared to women with a benign pelvic mass and 
other healthy controls.123 Preoperative identification of malignant pelvic masses, with 
or without irregular vaginal bleeding, is a great clinical challenge for tumours 
originating from the uterus as well as the fallopian tubes or the ovaries. In particular it 
may be of interest to evaluate plasma GDF-15 as a marker for uterine sarcomas where 
no marker is available in the clinical setting to distinguish preoperatively between the 
very commonly occurring benign myoma uteri and the rare but highly malignant 
sarcoma of the uterus. 
An expansion of data registered in the population based Norwegian Cancer Registry 
to include more detailed clinical-, histopathological- and therapy related data for 
endometrial cancer patients, may in the future be helpful to evaluate the overall 
quality of the treatment offered, and potential related survival effects. 
98
Errata 
Corrections in bold: 
Paper I:  p 645, Table 3: Foot note, line 1;” *One-sided Pearson chi-square test.” 
should read : *One-sided Mann-Whitney test. 
Paper III: p 4826, GDF-immunoassay section, last line”12.2% or more” should read: 
“12.2% or less”. 
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